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ABSTRACT OF DISSERTATION 
 
H2S AS A NOVEL BIOMARKER AND THERAPEUTIC TARGET FOR 
ASTHMA 
 
Asthma is a chronic inflammatory disease with hyper-responsive bronchoconstriction 
and airway remodeling, leading to extensive airway narrowing. The pathophysiology 
of asthma remains unclear. The literature shows that the cystathionine gamma lysase 
(CSE)/ hydrogen sulfide (H2S) system participates in the regulation of airway 
contractility and immune response. In this PhD thesis study we found that CSE was a 
major enzyme responsible for endogenous H2S synthesis in the lung and spleen. CSE 
gene knock-out (CSE-KO) dramatically decreased H2S production rates in these two 
organs. In an asthma model established via ovalbumin (OVA)-sensitization and 
challenge, airway resistance of CSE-KO mice (12-16 weeks old), in response to 
aerosolized methacholine (MCh) at 12.5 mg/ml, was two times higher than that of 
wild type (WT) mice (12-16 weeks old). CSE-KO mice also developed more 
peribronchial inflammation and had higher levels of type-2 helper T cell (TH2) 
cytokines in bronchoalveolar lavage fluid (BALF). As allergic asthma is more 
prevalent among children than in adults, we next used young (3-4 weeks old) and old 
(7-8 months old) mice to observe whether the CSE/H2S system was involved in early 
onset asthma. With the same intensity and duration of OVA-treatments, young WT 
mice developed much more severe asthma with greater lung resistance, higher levels 
of eosinophils and TH2 cytokines in BALF, and more peribronchial inflammation 
than did old WT mice. This age-dependent propensity for immunoreaction and 
asthma development resulted from lower levels of CSE expression and H2S 
production in splenocytes from young mice, which was reversed by H2S 
supplementation. Human umbilical cord blood mononuclear cells also had lower level 
of CSE proteins than peripheral blood mononuclear cell from human adults. CSE-KO 
mice had more severe asthma than WT mice but without age-dependent variation. 
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Lower endogenous levels of CSE/H2S promoted the differentiation of splenocytes 
into type-2 cytokine-generating cells in young WT mice and in CSE-KO mice at all 
ages. This effect was suppressed byH2S supplementation. CSE/H2S-induced 
inhibition of type-2 immunity was not mediated by STAT-6 activation. Instead, H2S 
caused S-sulfhydration of GATA3 in splenocytes and decreased GATA3 nuclear 
translocation, leading to the inhibition of type-2 immunity. We also found that CSE 
expression in the airways of WT mice increased in an age-dependent manner. In the 
absence of allergen exposure, lower abundance of CSE in young WT mice or absence 
of CSE in young/old CSE-KO mice aggravated airway responsiveness to MCh 
challenge by more than twice compared to old WT mice. In conclusion, CSE/H2S in 
peripheral lymph tissues and the lung suppresses allergen-induced type-2 immunity, 
airway responsiveness and the consequential asthma. Lower activity of the CSE/H2S 
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This chapter is an updated version of the original review article we published in 
Experimental Physiology, 2011 Sep; 96(9): 847-52. It is reproduced with permission 
from the publisher. Recent advances in asthma and hydrogen sulfide (H2S) research 
have been added. Updated sections are denoted with italic subtitles. 
 
Asthma is a chronic inflammatory disease, with hyper-responsive bronchoconstriction 
and airway remodelling, leading to extensive airway narrowing. The regulation of 
airway responsiveness and inflammation by endogenous H2S during the pathogenic 
development of asthma has been suggested. Hydrogen sulfide can be produced in the 
lung and airway tissues via the actions of two H2S-generating enzymes, cystathionine 
β-synthase (CBS) and/or cystathionine gamma-lyase (CSE). Abnormal metabolism 
and function of H2S have been reported in experimental animals with asthma, 
especially in rat or mouse ovalbumin-induced asthma models. In patients with 
asthma, serum H2S levels are significantly reduced. Supplementation with exogenous 
H2S has been shown to mitigate the severity of asthma in experimental animals. It is 
hypothesized that decreased H2S production in the lung and airway tissues may be 
used as an early-detection biomarker. H2S-based therapy would represent a new 
treatment strategy for asthma. Major challenges for establishing the diagnostic and 
treatment values of H2S include the differential expression of CSE and CBS in 
airways and their changes during asthma, the effects of H2S on bronchoconstriction 
and airway remodelling, as well as the underlying mechanisms, and the detection of 
the changes in H2S levels in airway tissues and in exhaled air. 
 
1.1 Pathological Features and Phenotypes of Asthma 
Asthma is a chronic inflammatory disorder of the airways, involving pathological 
changes in different types of cells and molecules. During asthma, activated mast cells, 
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increased eosinophils, T-helper 2 (TH2) lymphocytes and neutrophils, epithelia cells, 
airway smooth muscle cells, fibroblast cells, pulmonary blood vessel smooth muscle 
cells, and endothelia cells release inflammatory factors to cause classic pathological 
changes such as subepithelial fibrosis, airway remodelling and airway hyper-
responsiveness to allergens1 (Fig.1-1). Inhaled corticosteroids and long-acting β2-
adrenoceptor agonists are now the mainstay of asthma treatment. These agents 
suppress airway inflammation and decrease bronchoconstriction, but they cannot cure 
asthma. In addition, approximately 5% of asthma patients are corticosteroid resistant2. 
The search is ongoing to develop novel or improved therapies for asthma, which 
include anti-IgE therapy, cytokine inhibitors, chemokine antagonists, 
phosphodiesterase-4 inhibitors and adhesion molecule blockers2.  However, many of 
these experimental treatments are limited in their therapeutic capabilities2,3. For 
example, inhibition of interleukin-5 with mepolizumab results in the depletion of 
eosinophils from the circulation and sputum of patients with modest asthma, but has 
no effect on airway hyper-responsiveness and other symptoms or altered lung 
function in asthma4. In contrast, for the subgroup of asthmatic patients who have >3% 
eosinophils in their sputum, mepolizumab is effective in reducing asthma symptoms 
and preventing exacerbations5,6. These discrepancies highlight the clinical 
heterogeneity of asthma.  
 
Clinically-based definitions of asthma distinguish phenotypes such as atopic and 
allergic asthma, adult-onset asthma, obesity-related asthma, smoking-related asthma, 
neutrophilic asthma, and exercise-induced asthma7. Recently, researchers adopted 
unbiased statistics methods such as latent class analysis (LCA)8 and cluster analysis9 
to define asthma. Fig.1-2 shows 5 phenotypes of adult asthma established by Haldar P 
using cluster analysis. Results based on unbiased strategies overlap with those 
obtained using earlier clinical approaches. Age at disease onset has been found to be a 
key-differentiating factor of asthma phenotypes. Early-onset asthma is consistently 
related to atopic and allergic conditions, whereas later-onset asthma is generally less 
allergic, and more likely to be associated with obesity and eosinophilic or 
neutrophilic inflammation.  
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Early-onset asthma compared with later-onset asthma, is more likely to have higher 
amounts of TH2 cytokines (type-2 cytokines), total and allergen-specific IgE, and be 
concomitant with other atopic diseases, such as allergic rhinitis and atopic dermatitis9-
11. A large portion of persistent adult asthma originates in early childhood and has an 
atopic and allergic component. Results from the Third National Health and Nutrition 
Examination Survey12 and a community-based birth cohort from Perth13 revealed that 
over 50% of asthma cases could be attributed to atopy. 
 
Childhood asthma generally manifest as wheezing. Wheezing is a common symptom 
in early childhood but many children who wheeze do not develop asthma by school 
age14. Multiple wheezing phenotypes and several asthma predictive phenotypes have 
been identified in large, longitudinal cohort studies of the general population, 
including Tucson Children’s Respiratory Study15, Avon Longitudinal Study of 
Parents And Children (ALSPAC) study16, and a New Zealand longitudinal study17. 
According to ALSPAC, the most common phenotype is infrequent or transient 
infantile wheeze: approximately 75% of children in the general population were 
reported to have recurrent wheeze during the first 2–3 years of life but rarely 
afterwards. 9% of children have prolonged early wheeze with wheezing until 4.5 
years of age and remitting by the age of 6. These children have increased airway 
responsiveness and lower school-aged lung function compared with the first 
phenotype. Intermediate-onset wheeze was seen in 3% children. In this phenotype, 
wheezing begins between 1.5 and 3.5 years of life and persists into later childhood. 
These children are characterized by allergic sensitization, higher levels of airway 
responsiveness, and lower lung function compared with the first phenotype. Late-
onset wheeze (6%) defines children who have infrequent wheezing during their 0.5 to 
3.5 years of life, but subsequently develop frequent wheezing. 7% of children already 
have persistent wheezing by the age of 6 months. They constitute the final group,  
"persistent wheeze" phenotype.  
 
The intermediate-onset, late-onset, and persistent-wheeze groups may represent 
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asthma-predictive phenotypes meaning that children within these groups are most 
likely to experience recurrent asthma symptoms in later life18. Higher prevalence of 
TH2 markers were seen in these three phenotypes compared to other wheezing 
phenotypes in the ALSPAC study and the Prevention and Incidence of Asthma and 
Mite Allergy (PIAMA) study14,19. 
 
1.2 Asthma Prevalence 
A sharp increase has been seen in the global prevalence, morbidity, mortality, and 
economic burden associated with asthma over the last 40 years. After combining data 
from the Phase 1 International Study of Asthma and Allergies in Childhood (ISAAC, 
patients aged 6 to 7 years and 13 to 14 years) study20,21 and the European Community 
Respiratory Health Survey (ECRHS, adults aged 20 to 44 years) study22, the Global 
Initiative for Asthma (GINA) estimated 300 million people worldwide had asthma. 
They predict this number will increase to 400 million by 202523. Findings from the 
cross-sectional World Health Survey show global prevalence of clinical asthma in 
adults is 4.5% and ranges from 1.0% in Vietnam to 21.5% in Australia (Fig. 1-3)24. 
Prevalence of asthma is higher (> 10%) in developed countries than in developing 
countries, but in recent years rates are increasing in developing regions as they 
become more westernized23,24.  
 
The greatest increase in asthma prevalence is seen in children (Fig.1-4)25. Asthma 
currently is the most common chronic disease among children and young adults. 
Acute asthma is the leading cause of hospital admission among children of all ages in 
Europe25. The 2001--2009 American National Health Interview Survey showed 
persistent age differences in asthma prevalence: prevalence among children (age <18 
years) was 9.6% while prevalence among adults was 7.7%26. A study based on 
European Community Respiratory Health Survey (ECRHS) data, including 9091 men 
and women randomly selected from the general population at 29 centres from 14 
countries, also showed that the incidence of allergic asthma decreased significantly 
with age27. Sequential phases of ISAAC studies showed that the percentage of 
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children with asthma symptoms increased significantly in Africa, Latin America and 
parts of Asia28 over a 10-year period. Although overall prevalence of asthma is still 
lower in these lower income countries compared to more affluent countries, the 
prevalence of severe asthma has been higher29. This might be due to limited asthma 
care resources or lower awareness of wheeze as a marker of childhood asthma in 
those countries.  
 
The prevalence of asthma among migrating populations was studied in phase three 
ISAAC by comparing data from Vancouver, Canada, with data from centres in 
China30. Prevalence of asthma was lowest in Chinese adolescents born and residing in 
mainland China, intermediate for Chinese adolescents who migrated during their 
childhood to Canada and highest for Chinese-Canadian adolescents who were born 
and raised in Canada. 
 
1.3 Why Is Asthma Prevalence Increasing? 
Geographic variation in asthma prevalence, the rise of asthma incidence seen in 
migrating populations30,31and the substantial increase in asthma prevalence within 
these few decades, support the hypothesis that environmental factors play a large role 
in the current asthma epidemic. Data on environmental exposures, collected in birth 
cohort studies, reveal that events and exposures in utero, in early infancy and during 
the preschool years have long term effects on asthma development. The risk of 
developing asthma is age-dependent, with the majority of asthma beginning in the 
preschool years (Fig.1-5)32,33. More than 130 birth cohorts focusing on asthma and 
allergy have been initiated within the last 30 years34. These cohort studies utilize 
multidisciplinary/multiparameter phenotypic assessments of subjects and track 
recruited populations throughout childhood and, where feasible, into adulthood, 
providing us with new insights into the development, persistence, remission and/or 
relapse of the disease.  
 
These birth cohort studies identified two asthma risk factors: lower respiratory viral 
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infections and early life sensitization32,35. The asthma-predictive wheeze phenotypes 
(persistent, intermediate-onset, and late-onset wheezing phenotype) manifest higher 
prevalence of early sensitization to aeroallergens and associated TH2 response14,19. 
Common aeroallergens associated with sensitization and asthma include house dust 
mites (HDM), furred pets, cockroaches, rodents, and mold36.  
 
Wheezing due to viral infections is very common during childhood, especially during 
the first years of life. For example, Tucson Children's Respiratory Study found 30% 
of children had at least one lower respiratory infection associated wheezing in the 
first 3 years of life14. Allergic sensitization preceded and increased the risk of 
wheezing in response to rhinovirus37. Symptoms in non-atopic children with virus-
induced wheeze resolved by the early school years and normal lung function was 
retained14,38. In contrast, children who became sensitized to aeroallergens were much 
more likely to remain symptomatic into late childhood/adulthood and had lower lung 
function at school age14,39-41. 
 
Ulrik and Backer 42 assessed pulmonary function and atopy status of a group of 
children (7-17 years of age at enrollment) and reassessed them 6 years later. They 
found sensitization to house dust mites had a negative impact on the expected age-
related rise in FEV1 (forced expiratory volume in 1 second). Children with either 
persistent or new atopy to house dust mites had lower lung function than those who 
remained unsensitized. 
 
Longitudinal follow-up of birth cohorts in England41and Australia40,43showed that 
early sensitization was a risk factor for persistence of asthma. Western Australian 
Pregnancy Cohort Study confirmed atopy in early life increased risk of asthma 
independent of lower respiratory tract infections13. Furthermore, in many cases, 
exposure and sensitivity follow a dose–response relationship. The German 
Multicentre Allergy Study and a longitudinal birth cohort in Boston area found that 
exposure to high levels of perennial allergens early in life further aggravated this loss 
of lung function at school age39 and conferred greater risk of asthma44.  
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The asthma-promoting effect of early sensitization may result from its associated 
intense TH2 polarized effector and long-term memory responses. In a longitudinal 
study45, Turner et al. grouped 60 children into persistent infant-onset atopy (positive 
skin prick testing in infancy and at ages 6 and 11 years); early childhood-onset atopy 
(negative skin prick testing in infancy but positive at 6 and 11 years); and late 
childhood-onset atopy (negative skin prick testing in infancy and at 6 years but 
positive at 11 years of age). After testing peripheral blood mononuclear cell cytokine 
responses to HDM at 11 years of age, they found sensitization at an early age was 
associated with enhanced TH2 cytokine responses and adverse asthma outcome. Mice 
immunized as neonates or at a young age (4 weeks or 8 weeks), but not those 
immunized at an older age (30-40 weeks), mounted TH2-type-dominant memory 
responses and other asthma features when re-exposed to the same antigens 46.  
 
TH2 bias response is developed in utero to avoid maternal rejection47. TH2 cytokine, 
IL-4, drives apoptosis of TH1 cells and skews neonatal immunity toward TH2 through 
IL-13Ralpha1 which is upregulated in neonatal TH1 cells48. Murine neonatal CD4+ 
lymph cell are deficient in mounting antigen-specific TH1 response in adoptive adult 
hosts49. 
 
After birth, the neonatal immune system undergoes extensive development and 
gradually limits TH2 response and promotes TH1 response. The kinetics of postnatal 
immune maturation processes vary in human populations. An increased or prolonged 
bias towards TH2 response increases the risk of allergic asthma development50. For 
example, allergen-specific TH2 response, measured by cytokine mRNA levels in cord 
blood mononuclear cells, is higher than in peripheral blood mononuclear cells from 
one-year old infants. This suppression of TH2 response is not observed in atopic 
children51, suggesting their immune maturation lags behind non-atopic children. 
Lower expressional levels of interferon gamma (IFNγ), the major TH1 cytokine, at 
birth or in the first year of life are related to increased risk of wheeze and 
development of other atopic diseases52,53. TH1 response is critical for repelling 
 8 
intracellular pathogens; its deficiency may explain the high susceptibility to 
respiratory virus infections (such as rhinovirus and respiratory syncytial virus) in 
early childhood. In addition, these infections further alter immune responses and 
airway function and promote asthma development, especially in atopic children54. 
 
Clinical cohort studies have found that exposure to a microbially-rich environment in 
utero or early childhood was inversely related to incidence of childhood asthma. 
These exposures include, but are not limited to, growing up on a farm with 
livestock55, ingestion of raw cow milk56, and presence of dogs in the home. For 
example, PARSIFAL (Prevention of Allergy — Risk Factors for Sensitization 
Related to Farming and Anthroposophic Lifestyle) study, GABRIELA 
(Multidisciplinary Study to Identify the Genetic and Environmental Causes of 
Asthma in the European Community [GABRIEL] Advanced Study) and other studies, 
compared children who were raised on farms with those raised in the same rural 
communities but away from farms, or those raised in cities57,58, and consistently 
found protective effects of living on a farm against asthma development (Fig. 1-6, 
Fig. 1-7). The protection was strongest when exposure occurred in utero, or within the 
first 2–3 years of life. The Protection against Allergy--Study in Rural Environments 
(PASTURE) birth cohort demonstrated that maternal farm-related exposures during 
pregnancy reduced prevalence of seasonal allergen-specific IgE responses in cord 
blood mononuclear cells and enhanced TH1 response59. The Allergy and endotoxin 
(AlEX) study found that first year farm exposure suppressed grass-elicited TH2-
dependent immunoglobulin class-switch towards IgG1, IgG4 and IgE isotypes60.  
 
The protective effects of farm exposure are believed to be mediated by the increased 
amount and greater diversity of early gut microbial colonization, which subsequently 
triggers maturation of the developing neonatal immune system. Gut microbiota is of 
low density and phylogenetic diversity after birth61,62. Successive colonization of 
Gram-positive cocci, Enterobacteria, Lactobacilli, Bifidobacteria etc. happens in the 
first few weeks (in mice) or few years (in humans) of life. This process can be 
promoted by early life events such as breastfeeding, farm exposures and pet 
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ownership, or delayed by events such as caesarean section, and antibiotic usage. 
Normally, by the age of 3-5 weeks in mice or 3-4 years in humans, gut microbiota 
becomes comparatively stable with adult-like species diversity and population profile, 
although full development may take several more years in humans61,63. Delayed 
colonization, reduced diversity or disturbed balance of microbiota perturbs its 
immune regulatory functions. This notion is supported by an animal study in which 
germ-free animals exhibited persistent TH2 biased response and were more likely to 
develop allergic asthma than non-germ-free animals64. Colonizing germ-free animals 
with Bacteroides fragilis induced maturation of the developing immune system and 
downregulated splenic TH2 cytokine production64. 
 
The importance of microbiota in asthma development is illustrated in the evolved 
“hygiene hypothesis”. The “hygiene hypothesis” was first proposed by Strachan in 
1989 to elucidate the potential roles of improved hygiene in early life, reduction of 
family size and number of siblings (factors closely associated with the modern 
westernized lifestyle), as determinants of asthma susceptibility65,66. The hygiene 
hypothesis has been extended to include the interaction between microbiota and host 
immune balance. According to the updated theory, a modern/industrialized lifestyle 
leads to altered microbial diversity and loss of coevolved commensal microbes that 
have a strong effect on host immune responses67. The resulting dysbiosis fails to 
assist the host immune system in developing tolerance towards non-harmful antigen 
exposures and thus results in allergic disorders. The extended hygiene hypothesis is 
supported by studies performed in Eastern and Western European countries which 
showed significant differences in asthma prevalence and in the composition of gut 
flora between these two populations68.  
 
Taken together, environment factors have profound influences on asthma 
development. Early sensitization to aeroallergens and lower respiratory tract viral 
infections in early life collectively or independently skew immune response towards a 
TH2 dominated phenotype and contribute to asthma inception37. On the other hand, 
exposures to microbial-rich environments promote balanced immune system 
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development and prevent both allergic sensitization and transient early wheezing69. It 
is critical to test the hygiene hypothesis in more clinical studies as this hypothesis 
implies that asthma incidence may be lowered simply by modifying lifestyle factors 
rather than requiring sophisticated medical interventions.   
 
1.4 How is H2S Related to Asthma Development? 
1.4.1. Physiology of H2S metabolism in the lung  
Endogenous H2S is produced in many tissues, primarily by two H2S-generating 
enzymes, cystathionine β-synthase (CBS) and cystathionine gamma-lyase (CSE). 
Working together with cysteine aminotransferase (CAT), 3-mercaptopyruvate sulfur 
transferase (MST) may also produce H2S in selective tissues70. Abundant levels of 
CSE and MST have been found in sea lion pulmonary arteries and bovine pulmonary 
arterial smooth muscle cells (SMCs)71. Human airway SMCs and human lung 
primary fibroblast MRC-5 cells both express CSE and CBS proteins72,73. In rat lungs, 
CSE is expressed in airway and pulmonary vessels74. In mouse lungs, we recently 
found that both CSE and CBS are mainly expressed in airway SMCs, pulmonary 
blood vessel SMCs and endothelial cells (Fig. 1-8). It appears that the expression 
patterns and extent of H2S-producing enzymes in the lung and airway tissues are 
variable depending on the species and cell types. 
 
1.4.2. Altered H2S metabolism and the pathogenesis of asthma 
Wu et al.75 noted that the serum level of H2S decreased from 75.2 ± 13.0 µM in 
healthy adult subjects to 55.8 ± 13.6 µM in patients with stable asthma and 31.3 ± 2.9 
µM in patients with a severe acute exacerbation of asthma. In patients with acute 
asthma, serum H2S levels correlated positively with forced expiratory volume and 
negatively with the amount of inflammatory cells in sputum, especially neutrophils. 
Whether the drop of serum H2S in asthma patients is the cause or the consequence of 
asthma development has not been addressed. It is also not clear whether the 
pulmonary production of H2S was altered in these patients. At any rate, these clinical 
observations were replicated in a later animal study. Chen et al.74 found that 
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ovalbumin (OVA) treatments in rats led to 81% reduction of serum H2S and 80% 
decrease in the rate of H2S production in the lung. These decreases might be due to 
impaired CSE expression in lung tissues from these OVA-treated rats. Chen et al.74 
also found that peak expiratory flow was 55.4% lower in OVA-treated rats than in 
control rats, and the proportions of eosinophils, lymphocytes and neutrophils in 
bronchoalveolar lavage fluid were significantly increased. Administration of 
exogenous H2S (NaHS) improved peak expiratory flow and alleviated airway 
inflammation and airway remodelling in this rat model. 
 
1.4.3. H2S and immune response  
Asthma is characterized by an exaggerated TH2 adaptive immune response. In asthma 
patients, aeroallergen exposures stimulate clonal expansion of T lymphocytes, 
particularly TH2 cells, which secrete cytokines such as IL-4, IL-5, IL-9, and IL-13. 
These TH2 cytokines orchestrate the allergic inflammatory cascade in asthma76. 
Various innate immune cells, including dendritic cells and type-2 innate lymphoid 
cells, have also been found to play an important role in promoting type-2 immune 
response77 (Fig. 1-9).  
 
Endogenous H2S enzyme CSE is expressed in human primary peripheral blood 
mononuclear cell (PBMC) and human T cell lines such as HUT-78 and Jurkat 
cells78,79. Nanomolar concentrations of H2S potentiate T lymphocyte activation in 
vitro as assessed by CD69 expression, IL-2 expression, and CD25 levels. Silencing 
H2S-producing enzymes impairs T cell activation which can be rescued by the 
addition of Na2S (sodium sulfide, 300 nM)79. H2S treatment increased IFN-γ and IL-
10 production in Jurkat cells78. Blocking CSE activity with PPG (dl-
propargylglycine) delayed heart allograft rejection and abrogated type IV 
hypersensitivity by inhibiting TH1 type factors T-bet, IL-12, and IFN-γ. H2S also 
modulates innate immune responses. For example, H2S up-regulates CD11b and G 
protein-coupled receptor kinase 2 in neutrophils and improves their migration and 
survival in sepsis induced by cecal ligation and puncture80.  
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1.4.4. H2S and pulmonary inflammation 
Both pro-inflammatory and anti-inflammatory effects of H2S have been reported in 
different lung disease models.  
 
1.4.4.1 Anti- inflammatory effects 
In a rat intra-tongue vein lipopolysaccharide (LPS) injection-induced acute lung 
injury (ALI) model, NaHS treatments increased mitochondrial activity in a dose-
dependent manner, lessened mitochondrial lipid peroxidation and mitochondrial 
swelling, and limited lung damage81. A bolus injection of Na2S (0.5 mg/kg) combined 
with continuous infusion at a rate of 0.2 mg/kg/h for 24 hours reduced burn- and 
smoke-induced fluid accumulation in the lung, improved pulmonary gas exchange 
and decreased mortality during the 96 h experimental period82. H2S administrated 
after burn and smoke inhalation also increased anti-inflammatory cytokine IL-10, 
decreased pro-inflammatory cytokine IL-1β, and significantly decreased mortality in 
mice83. 
 
In rats challenged with aerosolized live streptococcus pneumoniae, NaHS infusion at 
36 µM/kg/h reduced heart rate and body temperature and preserved mitochondrial 
function84. Using a ventilator-induced lung injury model, Aslami et al. found 
continuous infusion of NaHS reduced pulmonary inflammation and improved 
oxygenation in a dose-dependent manner. Although this NaHS treatment also 
reversibly lowered body temperature, the author believed its anti-inflammatory effect 
was mediated via other mechanisms because mere induction of deep hypothermia did 
not protect against inflammatory damage in the lung85. Microarray analysis revealed 
that H2S administration activated genes related to inhibition of inflammation and 
apoptosis such as Atf3 (activating transcription factor 3), an anti-inflammatory and 
anti-apoptotic regulator86.  
 
1.4.4.2 Pro- inflammatory effects 
CSE expression in the lung and serum H2S levels increase significantly in rats with 
acute pancreatitis-associated lung injury. Blocking CSE activity with PPG or 
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knocking out the CSE gene significantly alleviated lung damage87,88, which suggests 
that endogenous H2S generated by CSE may play a key proinflammatory role in acute 
pancreatitis-associated lung injury.  
 
It is still unclear whether H2S is pro- or anti-inflammatory in lung diseases. Variations 
in doses of H2S supplementation, administration routes, H2S releasing rate and timing 
of treatments may all contribute to observed controversies. For example, Francis et 
al.89 found inhalation of 1 or 5 ppm H2S during high tidal volume (HTV) ventilation 
had no effect on lung injury. Inhalation of 60 ppm H2S, however, upregulated 
pulmonary expression of inflammatory mediators such as chemoattractant CXCL-2, 
leukocyte adhesion molecules CD11b and L-selectin, and worsened lung injury. 
Notably, pre-treating the animals with a bolus infusion of Na2S (0.55 mg/kg) reduced 
pulmonary CXCL-2 and CD11b expression, elevated Nrf2-dependent antioxidant 
genes (NQO1, GPX2, and GST-A4) and attenuated pulmonary edema89.  
 
1.4.5. H2S and oxidative stress 
Mitochondrial dysfunction and oxidative stress are associated with the onset and 
progression of asthma90. Activated inflammatory cells generate more reactive oxygen 
species (ROS). In contrast, antioxidants reduce mitochondrial dysfunction and 
oxidative stress in asthmatic mice91. Antioxidants have been used to prevent and treat 
mitochondrial abnormalities in asthma patients92. Macromolecule antioxidants such 
as vitamins E and C cannot enter mitochondria to scavenge reactive oxygen species. 
In contrast, gasotransmitter H2S can freely cross both plasma and mitochondrial 
membranes. Once inside mitochondria, H2S acts as a reducing agent, decreasing 
oxidative stress and enhancing endogenous antioxidant defenses, leading to the 
preservation of both mitochondrial structure and function93. Hu et al.94 reported that 
H2S prevented rotenone-induced mitochondrial membrane depolarization, 
cytochrome c release and decrease in Bcl-2/Bax in a human-derived dopaminergic 
neuroblastoma cell line. These protective effects of H2S may be mediated by 
mitochondrial ATP-sensitive potassium (KATP) channels. To date, it is unclear 
whether H2S can attenuate airway inflammation and hyper-responsiveness in asthma 
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by affecting the mitochondrial/oxidative stress pathway. 
 
1.4.6. H2S and airway smooth muscle cells 
Higher airway responsiveness has been observed in both young humans and young 
animals compared with older people or animals46,95,96. Airway smooth muscle cells 
(ASMCs) are the final controllers of airway contraction. Hyper-responsiveness of 
ASMCs in early life increases risk of asthma in childhood97,98. Lung and airway 
smooth muscle maturation have been suggested as contributors to this age-dependent 
discrepancy in airway responsiveness at various levels, i.e. alterations of lung 
volume, elastic recoil, structure of the airway wall, interaction of the airway wall with 
surrounding lung parenchyma, and properties of airway smooth muscle cells, such as 
M2 and M3 muscarinic receptors levels in airway smooth muscle96,99.  
 
H2S induces smooth muscle relaxation via its actions on two different types of ion 
channels. One is the KATP channel located on vascular SMCs and the other is the 
small to medium conductance KCa channel located on vascular endothelial cells. The 
opening of these two channels by H2S leads to membrane hyperpolarization and 
smooth muscle relaxation. Therefore, H2S can be characterized as an endothelium-
derived relaxing factor100.  
 
In contrast to the abundant studies on various functions of H2S in the cardiovascular 
system, little is known about the physiological effects of H2S on the respiratory 
system. Perry et al.73 investigated the regulatory role of H2S on the proliferation of 
human airway SMCs. H2S supplementations, both the fast-releasing ‘donor’ NaHS 
and the slow-releasing ‘donor’ GYY4137, suppressed airway SMC proliferation and 
interleukin-8 release due to the inhibited phosphorylation of ERK-1/2 and 
extracellular regulated kinase1/2 p38 mitogen-activated protein kinase. These effects 
of H2S donors were not altered by the inhibitor of CSE or by the manipulation of 
KATP channel opening or nitric oxide (NO) levels. In other studies, administration of 
NaHS or the CSE blocker PPG alleviated or aggravated, respectively, airway hyper-
responsiveness in both the rat cigarette smoke exposure model and the OVA-induced 
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asthma model74,101. NaHS relaxed rat tracheal rings that had been precontracted with 
acetylcholine or potassium chloride in a concentration-dependent manner. However, 
this NaHS-induced relaxation was not blocked by inhibitors of nitric oxide synthase 
(NOS) or by denudation of epithelium101. A reduction in intracellular calcium level 
induced by H2S (due to reduced calcium influx) has been shown in airway smooth 
muscle cells, which may underlie the H2S-induced relaxation of airway smooth 
muscle102. Airway SMCs contribute not only to airway narrowing in asthma but also 
to bronchial inflammation through the secretion of inflammatory factors and 
recruitment and activation of inflammatory cells103. Given the high expression levels 
of H2S-generating enzymes in airway SMCs and the demonstrated muscle-relaxing 
effect of H2S, it is hypothesized that reduced endogenous H2S levels due to the down-
regulation of H2S-producing enzymes may constitute a significant factor in the 
pathogenesis of asthma. 
 
1.4.7. H2S and microbiota 
Gut microbiota can up-regulate CSE activity/expression and endogenous H2S 
production via metabolic products in the colon104. For example, gut microbiota 
synthesize pyridoxal 5′-phosphate, the cofactor for CSE activation. CSE expression 
can also be upregulated by butyrate105, an end-product of microbial fermentation of 
plant polysaccharides which cannot be digested by humans104. Products generated 
from the interaction between microbiota and the intestinal immune system, such as 
IL-10, also promote colonic CSE expression and H2S synthesis106. CSE activity, 
assessed by cystathionine consumption in the cecum, colon, small intestine, kidney, 
liver, aorta, heart, and brain, was lower in 11-12 weeks old germ-free mice compared 
to age-matched mice raised in a conventional specific pathogen-free (SPF) 
environment107. 
 
1.5 H2S as a Biomarker of Asthma 
Detecting the presence of or changes in asthma biomarkers in nasal air is an attractive 
approach for early detection of asthma symptoms, monitoring treatment effect and 
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evaluating asthma prognosis. An ideal biomarker of clinical relevance should be 
reliable and repeatable, sensitive and specific for intervention effects, and easy to 
sample and detect108. Biomarkers in nasal air can be detected non-invasively and 
repeatedly. A large number of inflammatory factors (including adenosine, ammonia, 
hydrogen peroxide, isoprostanes, leukotrienes, prostanoids, NO, peptides, and 
cytokines) have been studied in exhaled breath condensate. Some of these factors 
correlate with eosinophilic airway inflammation and the treatment schedule of 
corticosteroid therapy109. However, these biomarkers do not always reflect asthma 
severity or predict therapeutic outcomes110. There is a need for new biomarkers with 
high specificity and sensitivity for asthma; H2S represents a promising biomarker for 
asthma. 
 
As mentioned earlier, serum H2S correlates with airway inflammation and with the 
severity of different respiratory diseases. It appears that serum H2S may be used as a 
marker for airway inflammation and lower respiratory tract infections74,75. However, 
since many non-respiratory diseases can affect serum H2S levels, the measurement of  
blood H2S is non-specific as well as  invasive. As a gasotransmitter, H2S shares many 
attributes with NO and also exists in exhaled breath so it too can be sampled non-
invasively. As one of the most important breath markers of lung diseases, exhaled NO 
has been studied extensively in multiple conditions including asthma, chronic 
obstructive pulmonary disease and cystic fibrosis111. Because it is affected by 
pathophysiological conditions of oral and dental health, H2S in exhaled oral air does 
not accurately reflect H2S metabolism in the respiratory system. This oral 
contamination can be avoided by measuring nasal H2S. Although the specific 
variations in exhaled H2S during different phases of asthma are still uncertain, 
exhaled nasal H2S has great potential as a marker of the health or specific disease 
status of lung and airway tissues. It would be desirable to develop new technologies 
to detect H2S in nasal air as a biomarker for asthma as well as other respiratory 
diseases. 
 
1.6 Animal Asthma Models 
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One of the most frequently used animal asthma models uses ovalbumin challenges. 
The animals are sensitized using ovalbumin with an adjuvant, typically aluminum 
hydroxide, and then challenged with ovalbumin by nebulization or intranasal 
administration. Ovalbumin challenge induces antigen-specific TH2 cell responses. 
Activated TH2 cells produce TH2-associated cytokines such as IL-4, IL-5 and IL-13. 
The ovalbumin model replicates features of human allergic asthma including airway 
hyper-responsiveness, airway inflammation and airway remodelling. It should be 
noted, however, that asthma is heterogeneous in origin and that distinct phenotypes 
and different pathogenic mechanisms are probably involved. Some types of asthma 
are dependent on TH2 cell activation while others are not112. Ozone-induced asthma 
models, for example, are characterized by airway neutrophilia, natural killer T cell 
and macrophages but not eosinophilic or TH2 inflammation in the lung113. 
Nevertheless, ozone exposure in animals induces severe airway hyper-reactivity, a 
cardinal feature of asthma113. 
 
1.7 Technological Challenge of Detecting H2S in Nasal Air 
Measurement of H2S in exhaled breath, especially nasal air, is attractive because it 
best represents physiological conditions (because of minimal moisture loss and 
reduced contamination from oral sources). Breath samples contain very low 
concentrations of H2S and are characterized by high moisture levels; both these 
factors challenge the detection power and ability of analytical technologies. 
Moreover, H2S presents difficult chemical and physical properties for the detection 
technology.  
 
Technical challenges related to sampling are nasal air collection, choice of storage 
media and maintenance of sample integrity. Nasal air sampling in experimental 
animals requires devices that suit the animal physiology to ensure representativeness. 
Measurement of H2S in biological materials is difficult owing to its volatility, 
tendency to undergo oxidation, adsorption onto containers and the sample 
introduction system, and loss during processing. H2S is corrosive; acceptable results 
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can be expected only if inert materials (such as polytetrafluoroethylene (PTFE), 
polychlorotrifluoroethylene, vinylidene polyfluoride, polyamide, ethylene-propylene 
or high-quality stainless-steel) are used in sample collection, storage and sample 
introduction systems. 
 
Challenges in nasal air analysis include moisture tolerance and detection power. A 
limited number of analytical techniques have been used for measuring H2S in breath, 
biological tissues and fluids (Table 1-1). These include gas chromatography, 
electrochemical detectors, spectrophotometry, high-performance liquid 
chromatography and an optical fibre chemical sensor, although the elevated H2S 
values reported with the latter cast significant doubt on the accuracy of the technique 
in light of the low occurrence of H2S in human breath114,115. Improved technologies 
(such as selected ion flow tube mass spectrometry and proton transfer reaction mass 
spectrometry) show promise for real-time analysis of H2S levels in human breath114. 
Most techniques either fail to accommodate the high moisture in nasal air or lack 
sufficient sensitivity. Nevertheless, gas chromatography is the most widely used 
technique, perhaps due to its capability to separate and detect traces of volatile 
compounds and the high sensitivity possible using a combination of thermal 
desorption and pulsed flame photometric detection. 
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                                                       Figure 1-1 
 
 
Fig. 1-1 Airways in asthma undergo substantial structural remodeling. 
Histological sections of a medium sized airway from a person without asthma and a 
patient with severe asthma stained with Movat’s pentachrome stain. In asthma, the 
epithelium (Ep) shows mucus hyperplasia and hyper-secretion (blue), and thickening 
of the basement membrane (Bm). Smooth muscle (Sm) volume is also increased in 




                                                      Figure 1-2 
 
Fig. 1-2 Clinical phenotypes of adult asthma, identified by cluster analysis. 
Clusters of patients are plotted according to their relative level of symptoms and 
degree of bronchial eosinophilic inflammation. The graph highlights that patients 
with greater discordance between symptoms and inflammation are more difficult to 
treat and may be best followed up in specialized asthma centres. Reproduced from 
Ref. 116 with permission. 
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                                                      Figure 1-3 
 
 
Fig. 1-3 Worldwide prevalence of clinical asthma. Reproduced from Ref. 24 with 
permission. The graph was generated with data from the World Health Survey (2002-
2003). 70 of the 192 WHO member countries conducted this standardized cross-
sectional survey. 178,215 individuals aged 18 to 45 years self-reported on questions 
relating to physician-diagnosed asthma, clinical/treated asthma, and wheezing in the 







                                                       Figure 1-6 
 
 
Fig. 1-6 Prevalence of asthma and atopy among children living on farms as 
compared with reference groups. The PARSIFAL study population included 6843 
school-age children 6 to 13 years of age, and the GABRIELA study population 
included 9668 children between 6 and 12 years of age. Calculations of prevalence in 
GABRIELA were weighted on the basis of the total number of children who were 
eligible for inclusion in the study (34,491 children). This study was published in the 
New England Journal of Medicine in Feb 2011. Reproduced with permission from 
New England Journal of Medicine Ref. 57, Copyright Massachusetts Medical 
Society.    
 25 




Fig. 1-7 Relationship between microbial exposure and the probability of asthma.  
In both the PARSIFAL study and GABRIELA, the range of microbial exposure was 
inversely associated with the probability of asthma. The PARSIFAL study population 
included 6843 school-age children 6 to 13 years of age, and the GABRIELA study 
population included 9668 children between 6 and 12 years of age. This study was 
published in the New England Journal of Medicine in Feb 2011. Reproduced with 




                                                       Figure 1-8 
 
 
Fig.1-8 Distribution of cystathionine gamma-lyase (CSE) and cystathionine β-
synthase (CBS) in the lung tissues of mice. Immunohistochemical staining shows 
that the expressions of CSE (A) and CBS (B) are mainly located in airway smooth 
muscle cells (blue arrow), vascular smooth muscle cells (red arrow) and vascular 
endothelial cells (green arrow). Published in Experimental Physiology, 2011 Sep; 
96(9): 847-52. Reproduced with permission. 
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                                                      Figure 1-9 
 
 
Fig. 1-9 Primary sensitization of the airways in the induction of allergic-type 
asthma. Perturbation of airway epithelium with infection and pollutants provides the 
initial danger signal and activates innate signaling receptors. This leads to chemokine 
secretion from airway epithelial cells and trafficking of immature dendritic cells 
(DCs) to the mucosal epithelium. DCs respond to danger signals via pattern 
recognition receptors (PRRs), triggering their maturation into competent antigen-
presenting myeloid-type DCs. Once activated, mature DCs process allergens detected 
through processes extended into the airways, or by capturing allergens that have 
breached the epithelium. The allergen-loaded DCs then migrate to local lymph nodes 
where they interact with naive T cells via TCR, MHC class II and co-stimulatory 
molecules to drive differentiation of T cells. Additional epithelial-derived cytokines 
and chemokines such as IL-33, IL-25, CCL17, and CCL22 influence DC activation 




                                                      Table 1-1 
 
 
Table 1-1 Analytical techniques used for detection of H2S in biological samples. 




Hypothesis and Objectives 
 
Asthma is a chronic inflammatory disease with hyper-responsive bronchoconstriction 
and airway remodelling, leading to extensive airway narrowing. Patients with allergic 
asthma usually develop their symptoms within the first 1-3 years of life. High 
incidence of allergic asthma in children closely relates to a TH2 biased immune 
response after birth47. Multiple cohort studies consistently found that living on a farm 
during early life was protective against childhood asthma57. This protection is 
believed due to increased early gut microbial colonization, which subsequently 
triggers maturation of the developing neonate immune system.  
 
Gut microbiota not only produces significant amount of H2S117 but also up-regulates 
CSE in the hosting mammalian cells via its metabolic products such as pyridoxal 5′-
phosphate and butyrate104,105. CSE activity in cecum, colon, small intestine, kidney, 
liver, aorta, heart, and brain was lower in 11-12-week germ-free mice than in age-
matched non-germ-free mice107. Gut microbiota is of low density and limited 
phylogenetic diversity after birth61,62. Successive colonization with Gram-positive 
cocci, enterobacteria, lactobacilli and bifidobacteria happens in the first few weeks 
of life in mice and first few years of life in humans61,63. Consistent with the 
observations of germ-free animals and lower microbiota colonization in early life, 
CSE activity and expression levels in mouse liver are very low after birth and 
increase gradually until reaching their peaks at 3 weeks of age118. Considering the 
stimulatory effect of microbiota on CSE expression in host organs and the time frame 
of microbiota colonization after birth, there appears to be a direct correlation between 
the age-dependent colonization of microbiota and CSE expression in the host. It is 
reasoned that early-life microbial exposure may suppress systemic TH2 biased 
response via up-regulating CSE/H2S in mammalian host cells. 
 
Involvement of CSE/H2S in asthma development has been suggested in human and 
animal studies. Plasma levels of H2S were lower in patients with stable asthma and 
correlated negatively with the severity of asthma75. In animal allergic asthma models 
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(8-week-old rats or 12-week-old mice), H2S levels in plasma and lung tissues were 
lower than in non-asthmatic control animals74. Exogenous H2S supplementation 
reduced OVA challenge-induced airway hyper-responsiveness, eosinophil infiltration 
and TH2 cytokine levels in bronchoalveolar lavage fluid (BALF).  
 
Hypothesis of this study: endogenous level of CSE/H2S is a determining factor for 
asthma development via suppression of biased TH2 response and that age-dependent 
changes in CSE/H2S levels explain the higher incidence of asthma in childhood.  
 
The objectives of this study include: 
1. To explore the protective role of endogenous H2S against allergen-induced 
allergic asthma using both wild type (WT) and CSE-KO mice;  
2. To investigate whether CSE/H2S plays a key role in the initiation of childhood 
asthma; 
3. To examine the mechanisms underlying the asthma-modulating effects of H2S;  
4. To search for effective H2S-based treatment regimes. 
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2. Chapter 2 
 
MATERIALS AND METHODS 
 
2.1 Chemical and Antibodies  
Anti-mouse CD3ε, CD28, IL-4, and IFN-γ antibodies were purchased from 
eBioscience (USA). Anti-STAT6, phos-STAT6, STAT-4, phos-STAT4, GATA3 and 
Tbet antibodies were purchased from Santa Cruz Biotechnology (USA). Anti-CBS 
antibody was purchased from Abnova (Taiwan). Anti-CSE antibody was purchased 
from Proteintech (USA). Anti-3MST was purchased from Sigma-Aldrich (USA), 
Lambin B1 was purchased from Abcam (USA). Mouse IL-2, IL-4 and IL-12 were 
purchased from Peprotech (Canada). NaHS, ovalbumin (OVA), protein inhibitor 
cocktails, penicillin-streptomycin, β-mercaptoethanol, RPMI Medium 1640, 
methacholine (Mch), red blood cell lysis buffer and bovine serum albumin were 




For in vivo experiments, homozygous CSE knockout (KO) and age-matched wild-
type littermates (WT) on C57BL/6J × 129SvEv background were used119. All animals 
were under diurnal lighting conditions. All experimental procedures were approved 
by Lakehead University Animal Care Committee (ACC) and performed in 
accordance with the guidelines set by the Canadian Council on Animal Care (CCAC). 
All efforts were made to minimize suffering and the number of animals used. 
 
2.3 Allergic Asthma Model   
In chapter 3, 12-16 week old WT and CSE-KO mice were used to establish allergic 
asthma models. Animals were sensitized to OVA with two intraperitoneal injections 
(ip) of 40 µg OVA/1 mg Alumina/mouse (grade V; Sigma-Aldrich, St. Louis, MO) 
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emulsified in 2.25 mg of alum hydroxide (AlumImject; Pierce, Rockford, IL) in a 
total volume of 200 µl on day 0 and day 7. On day 21 to day 23, mice were 
challenged with 100 µg OVA in 40 µl PBS by intratracheal inhalation after being 
anesthetized with isofluorane (Baxter, Canada). Control groups were treated 
identically except treatment solutions did not contain OVA. 
 
In chapter 4, to investigate age-dependent development of allergic asthma, allergic 
asthma was induced in young and old mice (3-4 weeks old and 7-8 months old, 
respectively) (Fig. 4-1). 2 µg OVA per gram body weight and 5 µg OVA per gram 
body weight were used to sensitize and challenge old mice, respectively. Some 
animals were treated with NaHS (14 µM/ kg ip twice daily) starting two days prior to 
sensitization and continuing until two days after sensitization (day minus-2 through 
day 2 and day 5 through day 9) (Fig. 4-1). 
 
2.4 Measurement of Lung Function 
A resistance and compliance (R&C) system (Fig.2-1, Buxco, USA) was used to test 
airway resistance in response to increasing concentrations of aerosolized 
methacholine (1.56, 3.13, 6.25, 12.5 mg/ml) following procedures as listed below:  
1) Mice underwent acute non-recovery operation for trachea cannulation. The mice 
were anesthetized with Ketamine (100 mg/kg, ip) + Xylazine (8.5 mg/kg, ip). Then a 
1.5-2 cm longitudinal incision on the ventral side of the neck was made to expose the 
trachea. A silk suture (6-8 cm) was placed underneath the trachea with curved forceps 
before a small T-shaped incision was made on the trachea. A cannula was inserted 5-
8 mm into the trachea and secured with the suture. 2) The cannulated mice were 
mechanically ventilated with a Buxco FinePointe R&C system (Buxco, USA). Body 
temperature of the mice was maintained between 36.0 °C and 37.5 °C using a heating 
pad. 3) Mice were ventilated (tidal volume: 0.2 ml, frequency: 150 breaths/min), and 
exposed to methacholine (MCh) aerosol for 20 s, then dynamic resistance was 
measured for 3 min. The average dynamic resistance response was recorded for each 




2.5 Bronchoalveolar Lavage Fluid Collection  
Mouse lungs were flushed three times with 0.8 ml PBS/1% BSA to obtain BALF. 
Aliquots of the pooled, non-centrifuged BALF were used to count total live and dead 
cells using trypan blue exclusion. The remaining BALF was centrifuged and the 
supernatant was stored at -80°C for determining IL-4, IL-5, IL-13, and eotaxin levels 
with ELISA (R&D). Cyto-centrifuged samples were re-suspended with PBS to reach 
a final concentration at 8x105 cells /ml. 80 µl of the cell suspension was used for 
cytospin preparations. The obtained slides were stained with Wright–Giemsa stain 
(Sigma-Aldrich, USA) for white cell counting. At least 200 cells per slide were 
counted using a light microscope under 400 magnification. Percentages of 
eosinophils, neutrophils, macrophages and lymphocytes were calculated.  
 
2.6 Lung Histology 
Left lobes of lungs were fixed in 5 ml of 10% buffered formalin and embedded in 
paraffin. Lung samples were sectioned at 4 µm and stained with H&E reagents 
(Sigma-Aldrich, USA) following standard procedures. Briefly, slides were 
deparaffinized with Xylene (Sigma-Aldrich, USA) for 3 x 10 minute periods, then 
hydrated by sequential passage through 100% ethanol (2 x 3 min), 95% ethanol (3 
min), 70 % ethanol (3 min) and distilled water. The sections were stained with 
hematoxylin for 5 min and rinsed under running tap water for 15 min before 
differentiation in a 0.1% acid alcohol solution (1-3 s). After being well rinsed in 
ddH2O, the slides were counter stained with Eosin (Sigma) for 20 seconds. Slides 
were then dehydrated by sequential passage through 90% ethanol (2 x 3 min), 100% 
ethanol (2 x 3 min), and Xylene (2 x 5 min). Once dry, the slides were mounted with 
resinous mounting medium (Fisher, USA). Pathological changes were examined 
under a light microscope equipped with a camera (Olympus, Canada).  
 
To quantitatively analyze the pulmonary inflammatory response (in Chapter 4), H&E 
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stained lung sections were examined using light microscopy with x40 objective. 
Eosinophils surrounding seven bronchi were counted in each lung slide and the 
average number of eosinophils per bronchus was calculated. 
 
2.7 Immunohistochemistry 
The right lobes of the lungs were fixed in 5 ml of 10% buffered formalin for 6-10 
hours then transferred to a 10% sucrose Solution (130 mM Na2HPO4, 30 mM 
KH2P04, 10% (w/v) sucrose, 0.01% sodium azide, pH 7.2) for 24 h. The fixed lungs 
were put into vinyl molds, and mounted in frozen tissue matrix OCT. The tissues in 
OCT were frozen slowly and gradually on top of liquid nitrogen and then stored at -
80 °C until sectioning.  
 
The frozen lung tissues were cut at 5 µm and used to detect CSE and CBS following 
standard immunohistochemistry protocol: 1) The slides were thawed at room 
temperature for 10-20 min before being fixed in methanol for 10 min; 2) The fixed 
slides were then rinsed in PBS (3 x 5 min) and incubated in a 0.3% H2O2 solution in 
PBS for 10 min to block endogenous peroxidase activity; 3) The slides were rinsed in 
PBS (3 x 5 min). Non-specific bindings were then blocked with a blocking buffer (1x 
PBS/0.3% Triton-X 100/5% normal goat serum) for 60 min at room temperature in a 
humidified chamber; 4) Blocking solution was removed and the slides were incubated 
with 400 µl primary antibody (CBS and CSE were diluted at 1:200 in blocking 
solution) overnight at 4 °C in a humidified chamber; 5) Primary antibodies were 
removed by rinsing the slides in PBS (3 x 5 min). The slides were then incubated with 
400 µl secondary antibody (diluted at 1:400 in blocking solutions) at room 
temperature for 1 h in a humidified chamber; 6) Secondary antibodies were removed 
by rinsing the slides in PBS (3 x 5 min). The slides were incubated with 400 µl DAB 
(Sigma, USA) for 5-10 min until the desired color intensity was reached. DAB 
substrate solution was prepared by mixing 1 ml DAB chromagen with 1ml DAB 
buffer; 7) The slides were rinsed in PBS (3 x 5 min) and stained with Hematoxylin 
following the steps indicated in 2.6; 8) Finally the slides were dehydrated and 
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mounted with coverslips using resinous mounting medium. 
 
2.8 Western Blotting 
Tissues or cells were homogenized in ice-cold RIPA buffer (Thermo Scientific, USA; 
25 mM Tris-HCl, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). 
Protein inhibitor cocktails (Sigma, USA) were added to RIPA buffer right before use. 
Lysates were incubated on ice for 10 min and then centrifuged at 15,000 g at 4 °C for 
15 min. Protein concentrations of the supernatants were determined using Biorad 
protein assay (Bio-Rad, USA) following manufacturer’s instructions. The 
supernatants with equal amounts of protein were then mixed with sample buffer (4% 
SDS, 0.125 M Tris-HCl, 20% glycerol, 10% 2-mercaptoethanol, 0.015% 
bromophenol blue) and denatured at 100 °C for 10 min. 80 µg tissue protein samples 
or 60 µg cell protein samples were loaded per lane and electrophoresis was performed 
in 10% SDS–polyacrylamide gels. The gel was subsequently run in running buffer 
(Tris-base 25 mM, Glycine 192 mM, SDS 0.1% w/v) at 50 V for stacking gel and 100 
V for separating gel using the Mini-PROTEAN® Electrophoresis System - Bio-Rad 
(Bio-Rad Laboratories, Inc, USA). Proteins separated by the gel were then transferred 
to polyvinylidene difluoride membrane (PDVF, 0.45 µm pore size) using the mini-
trans blot Electrophoretic Transfer Cell (Bio-Rad Laboratories, Inc, USA). The PDVF 
membrane was blocked in non-fat milk (5%, w/v) in PBST (0.1% v/v Tween-20 in 
PBS) for 1 h at room temperature. The membrane was then incubated with primary 
antibody overnight at 4 °C followed by 1 h incubation with HRP linked secondary 
antibody (Sigma, USA) at room temperature. The bands were visualized using an 
ECL detection reagents kit (Biosciences, Canada) according to the manufacturer’s 
instructions. The blots were subsequently quantified using ImageJ software. 
 
2.9 Measurement of H2S Production in the Lung 
H2S production in the lung was measured following procedures described 
previously120. Briefly, mouse lung tissues were homogenized in ice-cold 50 mM 
potassium phosphate buffer (pH 6.8). For each reaction, 300 µl lung homogenate 
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were added to a mixture of 100 µl L-cysteine (100 mM), 100 µl pyridoxal 5’ 
phosphate (PDP, 2 mM), and 250 µl potassium phosphate buffer (0.4 M, pH 7.4). 300 
µl potassium phosphate buffers (50 mM), instead of lung homogenate, were added in 
blanks. Cryovial test tubes (2 mL) with a piece of filter paper (2 × 2.5 cm2) were used 
as the central wells, each containing 500 µl trapping solution (1% zinc acetate, 2% 
sodium EDTA, pH 12.7) to trap H2S. The flasks were flushed with N2 for 1 min and 
then sealed with Parafilm®. Reactions were initiated by transferring the flasks from 
ice to a 37ºC shaking water bath. After incubation for 90 min, 0.5 ml of 50% (w/v) 
TCA was injected into the flasks (central wells had to be avoided). The flasks were 
incubated in the shaking water bath at 37 ºC for another 60 min to trap H2S 
completely. Upon finishing incubation, all contents in the central wells were carefully 
transferred to a 15 ml testing tube with 3.5 ml ddH2O. 500 µl of 20 mM N, N-
dimethyl-pphenylenediamine sulfate (N, N-DPD in 7.2 M HCl) and 500 µl of 30 mM 
FeCl3 in 1.2 M HCl were added to the testing tubes in the stated sequences. After 
another 20 min of incubation at room temperature, the absorbance of the resulting 
solution was measured with a spectrophotometer at 670 mm. 
 
2.10 H2S Concentration Measurement 
H2S generated by splenocytes was measured as described by Kartha et al121 with 
modifications. In brief, splenocytes were cultured in 50 ml cell culture flasks, the tops 
of which were pre-coated with 5 ml zinc-agar. The composition of the agar layer was 
800 µl zinc acetate (45 mM, Sigma-Aldrich, USA), 180 µl NaOH (3 M, Sigma-
Aldrich, USA) and 4.02 ml sterilized agar (1% w/v, Sigma-Aldrich, USA). After 
being cultured for 72 h, the splenocytes and media were removed carefully without 
disturbing the agar layers. The culture flasks were then re-orientated with the agar 
layers down. 2 ml of N, N-dimethyl-p-phenylenediamine chloride (N, N-dpd, 40 mM 
in 7.2 M HCl; Sigma-Aldrich, USA) was added to each flask to incubate the agar 
layers for 10 min at room temperature. Iron chloride reagent of 400 µl (FeCl3, 30 mM 
in 1.2 M HCl; Sigma-Aldrich, USA) was then added and mixed with the N, N-dpd. 
After 20 min incubation, 200 µl of the contents in the flask were transferred to a 96-
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well microtiter plate. Absorbance was measured at 670 nm using a Synergy 2 Multi-
Mode Reader (BioTek, Winooski, USA). H2S concentration was calculated against a 
standard curve that was generated with NaHS (concentrations range from 5 to 250 
µM) using setups identical to the cell culture flasks. 
 
2.11 In vitro Re-stimulation Assay 
Spleens and mediastinal lymph nodes were collected 5 days after OVA sensitization 
from 6 mice per group (Supple. 4.1). Splenocytes and lymph node cells were prepared 
by mashing pooled mediastinal lymph nodes and spleens through a 40 µm cell 
strainer (BD Biosciences, USA). Erythrocytes from spleens were removed using Red 
Cell Lysis Buffer (Sigma-Aldrich, USA). Cells were seeded at a final concentration 
of 1 × 106/ml in 24-well plates and re-stimulated with OVA (100 µg/ml) for 72 h. IL-
4, IL-5 and IL-13 levels in the supernatant were tested with ELISA (R&D, USA) 
following the manufacturer’s instructions.  
 
2.12 TH2 Cell Differentiating Culture 
Spleens were collected from normal mice without any sensitization or treatment. 
Splenocytes were isolated following the method described in section 2.11. 
Splenocytes (200 µl 1 million/ml) were seeded in 96-well plates. Cells were cultured 
in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 500 
U penicillin-streptomycin (Sigma-Aldrich, USA) and 50 µM β-mercaptoethanol 
(Sigma-Aldrich, USA), anti-mouse CD3ε (5 µg/ml, plate-bound, 145-2C11; 
eBioscience, USA), anti-mouse CD28 (2 µg/ml, clone 37.51; eBioscience, USA), 
mouse IL-4 (20 ng/ml, Peprotech, Canada), mouse IL-2 (20 ng/ml, Peprotech, 
Canada) and anti-mouse IFN-γ (5 µg/mL, R4-6A2; eBioscience, Canada).  These 
conditions promote TH2 cell differentiation. In some experiments, NaHS (0.3, 1, 3, 
10, and 30 µM, Sigma-Aldrich, USA) was added to the culture medium. On day 3, 
the cells were passaged and cultured for an additional 3 days on 24-well plates 
containing IL-2 (20 ng/ml) andIL-4 (20 ng/ml) with or without the addition of NaHS 
(0.3, 1, 3, 10, and 30 µM). After the differentiation culture, splenocytes were re-
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stimulated with PMA/ionomycin (1:1000; Cat No. 00-4970, eBioscience) for 24 h. 
Culture medium was harvested and cytokine levels in the medium were measured 
with ELISA (R&D, USA). 
 
2.13 TH1 Cell Differentiating Culture 
Mouse splenocytes were isolated as described in section 2.11. Splenocytes (200 µl, 1 
million/ml) were seeded in 96-well plates. Cells were cultured in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal calf serum, 500 U penicillin-
streptomycin (Sigma-Aldrich) and 50 µM β-mercaptoethanol (Sigma-Aldrich), anti-
mouse CD3ε (5 µg/ml, plate-bound, 145-2C11; eBioscience), anti-mouse CD28 (2 
µg/ml, clone 37.51; eBioscience), mouse IL-12 (20 ng/ml, Peprotech) , mouse IL-2 
(20 ng/ml, R&D) and anti-mouse IL-4 (5 µg/ml, 11B11, eBioscience). These 
conditions promote TH1 cell differentiation. In some experiments, NaHS (0.3, 1, 3, 
10, and 30 µM) was added to the culture medium. On day 3, the cells were passaged 
and cultured for an additional 3 days on 24-well plates containing IL-2 (20 ng/ml) and 
IL-12 (20 ng/ml) with or without NaHS (0.3, 1, 3, 10, and 30 µM). After the 
differentiation culture, splenocytes were re-stimulated with PMA/ionomycin (1:1000; 
Cat No. 00-4970, eBioscience) for 72 h. Culture medium was harvested and IFN-γ 
levels in the medium were measured with ELISA (eBioscience, USA). 
 
2.14 ELISA 
IL-4, IL-5, IL-13, and eotaxin levels in BALF and cell culture medium were tested 
using a commercial ELISA kit (R&D, USA); IFN-γ levels in the medium were 
measured with mouse IFN gamma ELISA Ready-SET-Go (eBioscience, USA). 
ELISAs were performed according to the manufacturer’s protocols. 
 
2.15 Nuclear and Cytoplasmic Protein Extraction 
Splenocytes were cultured under TH1 or TH2 differential conditions for 4 days. 
Cytoplasmic and nuclear proteins were extracted using NE-PER Nuclear and 
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Cytoplasmic Extraction Reagent (Pierce, Thermo Scientific, USA) following the 
manufacturer’s instructions. Briefly, cells were incubated with Cytoplasmic 
Extraction Reagent (CER I) supplemented with protease inhibitors for 15 min and 
then CER II was added. After vortexing, cells were spun to pellet at 8000 rpm for 5 
min at 4 °C. The supernatant (cytoplasmic extract) was removed and stored at -80 °C 
until use. The nuclear pellets were resuspended in ice-cold Nuclear Extraction 
Reagent (NER) supplemented with protein inhibitors and vortexed on the highest 
setting for 15 s (every 10 min, for a total of 40 min). The lysed nuclei were 
centrifuged at 16,000 g) for 10 min. For nuclear translocation assays, nuclear and 
cytosolic proteins were immunoblotted with mouse anti-GATA3 antibody (1:200, 
Santa Cruz Biotechnology, USA). 
 
2.16 Reactive Oxygen Species Detection  
Freshly isolated splenocytes were cultured for 24 h in plates with or without pre-
coated anti-CD3ε antibody. Then ROS activities in splenocytes were measured using 
2′,7′-dichlorofluorescein diacetate (DCFDA) with the ROS assay kit (Abcam, USA). 
Briefly, approximately 1 × 106 splenocytes were incubated in 20 µM DCFDA for 
45 min at 37 °C according to the manufacturer′s instructions. Incubated cells were 
then washed with PBS and re-suspended in 1ml PBS. Fluorescence intensity of a 
single splenocyte was measured using flow cytometry (λex = 485 nm, λem = 535 nm). 
 
2.17 Modified Biotin Switch Assay for S-sulfhydration Detection 
The S-sulfhydration assay was performed as described previously122. Briefly, HEK 
293 cells and spleen tissues were sonicated in HEN buffer [250 mM Hepes-NaOH 
(pH 7.7), 1 mM EDTA, and 0.1 mM neocuproine] supplemented with 100 µM 
deferoxamine. Lysates were centrifuged at 13,000 g for 30 min at 4 °C. Supernatant 
was added to blocking buffer [HEN buffer with 2.5% SDS and 20 mM methyl 
methanethiosulfonate (MMTS)] at 50 °C for 20 min with frequent vortexing. The 
MMTS was then removed with pre-chilled acetone and the proteins were precipitated 
at -20°C for 20 min. After acetone removal, the proteins were re-suspended in HENS 
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buffer (HEN buffer with 1% SDS). Biotin-HPDP (N- [6-(biotinamido) hexyl] - 3’-
(2’-pyridyldithio) propionamide) in dimethyl sulfoxide was added without ascorbic 
acid. After incubation for 3 h at 25 °C, biotinylated proteins were precipitated by 
streptavidin-agarose beads. Beads were washed five times with HENS buffer. The 
biotinylated proteins were eluted by SDS-PAGE sample buffer and subjected to 
Western blotting analysis using anti-GATA3 antibody (1:200, Santa Cruz 
Biotechnology, USA). 
 
2.18 Site-directed Mutagenesis of GATA3 
pFAG-GATA3 was purchased from Addgene (MA, USA). Single mutations at 
cyteine-84 (GATA3-C84), cysteine-182 (GATA3-C182), cyteine-248 (GATA3-
C248), cysteine-375 (GATA3-C375) and double mutation at cyteine-84/182 
(GATA3-C84/182) or cysteine-84/248 (GATA3-C84/248) were conducted using the 
Quick Change Site-Directed Mutagenesis kit (Stratagene, USA) 123. All primer 
sequences used in this study were listed in Table 4-1. The correct mutant was 
confirmed by DNA sequencing at the MOBIX lab of McMaster University, ON, 
Canada. 
 
2.19 Statistical Analyses 
Data analysis and graph generation were performed using GraphPad Prism Software 
version 5.0. Statistical differences were calculated using two-way ANOVA (for 
comparisons among WT-young, WT-old, KO-young and KO-old), and unpaired t 
tests (for comparisons between WT and CSE-KO or control and NaHS treatment 
groups). Mann Whitney test was used when variance was different between groups or 
data were not normally distributed. One-way ANOVA was used for comparing data 
among groups with various NaHS treatments. Results were considered significant at P 




3. Chapter 3 
 
The Inhibitory Role of H2S in Airway Hyper-responsiveness and Inflammation 
in a Mouse Model of Asthma 
 
[Data included in Chapter 3 were published in American Journal of Pathology, 2013 
Apr; 182(4): 1188-95. They are reproduced with permission from the publisher. The 
experiments conducted by other co-authors are referred to as Appendix 1 and 
Appendix 2. I assisted in these experiments by performing lung function tests and 
histological staining.]  
 
3.1 Abstract 
Cystathionine gamma-lyase (CSE) is one of the major enzymes producing H2S in 
lungs, participating in the regulation of respiratory functions. In allergic diseases, the 
role of CSE-derived H2S in eosinophil-dominant inflammation has been unclear. The 
objective of this study was to explore the protective role of H2S against allergen-
induced airway hyper-responsiveness (AHR) and inflammation. CSE expression and 
H2S production rates were assessed in lung tissues from mice with ovalbumin (OVA)-
induced acute asthma. AHR, airway inflammation, and TH2 response in wild-type 
(WT) mice were compared with those in CSE gene knockout (CSE-KO) mice. CSE 
expression was absent and H2S production rate was significantly lower in the lungs of 
CSE-KO mice when compared with WT littermates. OVA-challenge decreased lung 
CSE expression and H2S production in WT mice. CSE deficiency resulted in 
aggravated AHR, increased airway inflammation, and elevated levels of TH2 
cytokines such as IL-5, IL-13 and eotaxin-1 in bronchoalveolar lavage fluid after 
OVA-challenge. The aforementioned alterations were reversed by exogenous H2S 
treatment. More importantly, NaHS supplementation rescued CSE-KO mice from the 
aggravated pathological process of asthma. In conclusion, the CSE/H2S system 
appears to play a critical protective role in asthma development and may present new  




H2S, known for centuries as a noxious and toxic gas, is now recognized as a third 
gasotransmitter (after nitric oxide and carbon monoxide) with an important regulatory 
role in chronic respiratory diseases, and cardiovascular and metabolic disorders119,124-
127. The role of H2S in inflammation, however, is still controversial125. Some studies 
have showed that exogenous H2S has a pro-inflammatory effect in various 
inflammatory models including lipopolysaccharide-induced endotoxemia, acute 
pancreatitis, and cecal ligation and puncture-induced sepsis128-130. Other researchers 
have reported anti-inflammatory effects of H2S131-133. The concentration and the 
release rate of exogenous H2S donors are the main factors in determining whether 
H2S is anti-inflammatory or pro-inflammatory. High concentration and fast-releasing 
rate of H2S results in a pro-inflammatory effect while low concentration and slow-
releasing rate of H2S is anti-inflammatory133,134.  
 
Asthma is one of the most common chronic inflammatory diseases. Its prevalence has 
markedly increased throughout the past 2 decades135. Eosinophilia and TH2 cytokine 
production are two hallmarks of allergic asthma136. Increased TH2 cytokines (such as 
IL-4, IL-5, and IL-13) cause immunoglobulin isotype switching of B cells to produce 
IgE, promote the growth, maturation, and activation of TH2 cells and eosinophils, and 
result in airway hyper-responsiveness (AHR), mucus production, and airway 
remodeling136. Previous studies have shown the existence of CSE and/or 
cystathionine β-synthase (CBS) in peripheral lung tissues of mice and rats74,137. 
Decreased CSE expression and serum H2S levels were observed in the rat asthma 
model and in asthmatic patients74,75,138. Serum H2S level is positively correlated with 
lung function parameters such as forced expiratory volume in 1 second (FEV1) in 
both adult and pediatric asthma75,138, and negatively correlated with sputum counts of 
total cells and the percentage of sputum neutrophils75. These results suggest a 
possible role of endogenous H2S in the development of asthma. All of these previous 
studies, however, were based on neutrophil-dominant airway inflammation74,75 which 
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is different from the eosinophil-dominant airway inflammation in allergic asthma136. 
Whether endogenous H2S plays a role in the development of eosinophil-dominant 
inflammation, as occurs in allergic asthma and atopic dermatitis, remains unknown. 
 
Our previous studies have found that CSE is the main H2S-producing enzyme in 
peripheral tissues such as liver, pancreas, and aorta119,126. Compared to WT mice, 
endogenous H2S levels of CSE-KO mice were decreased by 50% in serum, and by 
80% in vascular tissues and pancreases119,126. The lower level of endogenous H2S in 
CSE-KO mice causes hypertension119, delays the onset of streptozotocin-induced 
diabetes126, promotes proliferation of smooth muscle cells139, and inhibits vascular 
endothelial growth factor-induced microvessel formation and wound healing140. To 
date, the exact role of endogenous H2S in systemic or local inflammation has not been 
studied by knocking out the CSE gene. Given the critical regulatory role of the 
CSE/H2S system in various physiological and pathological conditions, we 
hypothesized that the endogenous CSE/H2S pathway may play an important role in 
the pathogenesis of allergic asthma. 
 
In the present study, we induced asthma in CSE-KO mice and WT mice via OVA-
treatments. With these models, we examined the alterations of CSE expression and 
H2S production in the lung, as well as changes in AHR, airway inflammation, and 
TH2 response. In addition, the effects of exogenous H2S treatments on asthma 
development were observed in both WT and CSE-KO mice. 
 
3.3 Results 
OVA-Challenge Reduces CSE Expression and H2S Production Rate in the Lung 
Age-matched WT and CSE-KO mice (12-16 weeks old) were used to establish 
allergic asthma models following procedures listed in section 2.3. In CSE-KO mice, 
CSE proteins were not detectable in the lung (Fig.3 -1 A). Sensitized WT mice 
displayed a slight, but significant decrease in CSE expression in the lung after OVA- 
challenge (0.70 ± 0.05 versus 0.52 ± 0.03; P < 0.05) (Fig.3 -1 A). The levels of CBS 
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expression, another H2S-producing enzyme, were similar in the lungs of WT and 
CSE-KO control mice. Even after OVA-challenge, CBS expression was not changed 
in either WT or CSE-KO mice (Fig.3 -1 A). Rate of pulmonary H2S production in 
CSE-KO mice was four times less than that of WT mice (0.27 ± 0.04 versus 1.38 ± 
0.06 nmol/g per minute; P < 0.05) (Fig.3 -1 B). H2S production rate was reduced by 
40% in lungs of WT-OVA mice in comparison with WT-CON mice (0.83 ± 0.10 
versus 1.38 ± 0.06 nmol/g per minute; P < 0.05) (Fig.3 -1 B). In CSE-KO mice, 
OVA-challenge had no effect on lung H2S production (Fig.3 -1 B). 
 
CSE Deficiency Aggravates OVA-Induced Airway Inflammation, and Elevates 
Cytokine Levels in BALF  
No difference was detected in AHR to increased doses of MCh between WT and 
CSE-KO control mice (Fig.3 -2 A). OVA-challenge induced a significant increase in 
AHR in both WT and CSE-KO mice with the latter being more severe (Fig.3 -2 A). 
The resistance of lung (RL) in response to MCh at 12.5 mg/mL and 25 mg/mL was 2- 
and 1.62- fold higher, respectively, in CSE-KO-OVA mice in comparison to WT-
OVA mice (13.13 ± 1.58 versus 6.52 ± 0.56 and 26.25 ± 3.47 versus 16.18 ± 0.98 
cmH2O/mL per second, respectively, both P < 0.05) (Fig.3 -2 A). 
 
The number of leukocytes in BALF was not different between WT and CSE-KO 
control mice. However, OVA-challenge resulted in significantly greater counts of 
total cells and eosinophils in BALF from CSE-KO mice compared with WT mice 
(Fig.3 -2 B). The number of eosinophils in CSE-KO-OVA mice was almost threefold 
higher than that in WT-OVA mice (148.70 ± 16.63 versus 50.66 ± 11.35 × 104/mL; P 
< 0.05) (Fig.3 -2 B). Histological examination revealed widespread patchy 
inflammatory infiltrates around peribronchial and perivascular areas in lungs of WT-
OVA and CSE-KO-OVA mice with more serious infiltrates in the latter (Fig.3 -2 C). 
IL-4, IL-5, IL-13 and eotaxin-1 in BALF were hard to detect or found at very low 
levels in control mice, and increased significantly after OVA-challenge (Fig.3 -2 D-
G). Compared to WT-OVA mice, IL-5 and IL-13 were 3.49-fold and 1.75-fold 
higher, respectively in CSE-KO-OVA mice (Fig.3 -2 D, E). However, there was no 
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significant difference in IL-4 levels between the WT-OVA and CSE-KO-OVA 
groups (Fig.3 -2 F). Among OVA-challenged mice, eotaxin-1 level in BALF was 
higher in CSE-KO mice than in WT mice (90.25 ± 4.23 versus 41.13 ± 3.45 pg/mL; P 
< 0.05) (Fig.3 -2 G). 
 
NaHS Treatment Alleviates OVA-Induced AHR and Airway Inflammation and 
Lowers Cytokine Levels in WT Mice 
NaHS treatments of WT mice attenuated OVA-induced AHR in response to MCh at 
12.5 and 25 mg/mL compared with vehicle treatments (both P < 0.05) 
(Appendix 1A). Total and differential cell counts including eosinophils, macrophages, 
and lymphocytes were significantly decreased in BALF by NaHS treatments 
(Appendix 1B). Of note, the number of eosinophils was reduced almost by 50% after 
NaHS treatments compared to vehicle treatments (70.23 ± 7.41 versus 36.32 ± 8.71 × 
104/mL; P < 0.05) (Appendix 1B). Histological sections of the lung also showed less 
inflammatory cell infiltration in OVA-challenged WT mice after NaHS treatments 
(Appendix 1C). In assessment of cytokines in BALF, NaHS treatments significantly 
attenuated the OVA-induced IL-5, IL-13, and eotaxin-1 compared with vehicle 
treatments, whereas they had no significant effect on IL-4 (Appendix 1 D-G). As 
shown in Appendix 1, pretreatment with glybenclamide did not reverse the inhibitory 
effect of NaHS on the OVA-induced AHR, airway inflammation or cytokine levels in 
BALF. 
 
NaHS Supplementation Reduces Asthmatic Severity in CSE-KO-OVA Mice 
AHR to MCh at 12.5 and 25 mg/mL in KO-OVA mice was decreased (by 41.68% 
and 32.40% respectively) after NaHS treatment (10.94 ± 1.42 versus 6.38 ± 0.91 and 
22.93 ± 2.57 versus 15.16 ± 1.77 cmH2O/mL per second, respectively; both P < 0.05) 
(Appendix 2A). NaHS applications significantly reduced total and differential cell 
counts in BALF in comparison with vehicle treatments (Appendix 2B). Significantly, 
eosinophil counts in CSE-KO-OVA mice were reduced by 51% after NaHS treatment 
(105.2 ± 9.7 to 51.5 ± 6.7 × 104/mL; P < 0.05). Decreased inflammatory cell 
infiltrates in lung tissues were also observed after NaHS treatments in CSE-KO-OVA 
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mice (Appendix 2C). NaHS treatments significantly decreased the levels of IL-5, IL-
13 and eotaxin-1 in BALF compared to vehicle treatments whereas it had no effect on 
IL-4 (Appendix 2D). Moreover, NaHS treatment decreased IL-13 in CSE-KO-OVA 
mice to the basal level (Appendix 2D). 
 
3.4 Discussion 
CSE is a major H2S-production enzyme in mouse lungs, although at least one other 
pulmonary H2S-producing enzyme (CBS) exists127,137. Lung CSE expression in WT 
mice was significantly reduced after OVA-challenge, accompanied by a significant 
decrease in H2S production (Fig. 3 -1 B). The OVA-challenge, however, had no effect 
on lung CBS expression, even when CSE was deficient (Fig.3 -1 A). Based on these 
results, it is suggested that the decrease in endogenous H2S production in WT mice is 
due to reduced CSE expression after OVA-challenge. TH2 cytokines, such as IL-4 and 
IL-13, can down-regulate CSE expression and activity in human airway smooth 
muscle cells. It is likely that elevated TH2 cytokines, produced by inflammatory cells 
which influx to the lung after OVA-challenge, suppressed CSE expression and 
consequent H2S production in the lung.  
 
Accumulating evidence has shown altered endogenous H2S metabolism and a 
potentially protective role of exogenous H2S in many conditions of neutrophil-
dominant inflammation131-133. Herein, we investigated the role of the endogenous 
CSE/H2S system in eosinophil-dominant airway inflammation. In CSE-KO mice, 
CSE deficiency and lower H2S production in the lung caused profound airway 
inflammation, elevated levels of TH2 cytokines, and aggravated AHR after OVA-
challenge (Fig.3 -2). Exogenous H2S supplements to WT-OVA mice or KO-OVA 
mice, on the other hand, decreased or reversed OVA-induced AHR, reduced 
inflammatory infiltration and alleviated airway remodeling (Appendix 1, Appendix 
2).  
 
TH2 cytokines orchestrate inflammatory cascades in asthma. For example, IL-4 
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facilitates naïve T cell differentiation into TH2 cells; IL-4 and IL-13 induce isotype 
switching to IgE production in B cells; IL-5 promotes eosinophil maturation and 
survival141. These mature eosinophils were then recruited into the lung by 
eotaxin136,142,143. Deficiency in CSE boosted OVA-challenge-induced IL-5, IL-13 and 
eotaxin-1 production, which led to increased eosinophil infiltration in the lungs of 
CSE-KO mice. Exogenous H2S supplementation significantly decreased cytokine 
levels of IL-5, IL-13 and eotaxin-1, and reduced, even rescued, OVA-induced 
eosinophilic airway inflammation in WT-OVA mice and in KO-OVA mice. These 
results suggest that endogenous and exogenous H2S protects against the development 
of OVA-induced allergic airway inflammation by suppressing TH2-associated 
cytokine expression and reducing eosinophil recruitment.  
 
The exact molecular mechanism underlying the inhibitory role of H2S in 
inflammation is still not well understood. Studies have shown that H2S is involved in 
regulation of anti-inflammation through inhibition of NF-κB activation133,144. 
Recently, a direct effect of endogenous H2S on NF-κB activation has been 
reported145. CSE-generated H2S directly sulfhydrates the p65 subunit of NF-κB at 
cysteine-38, and then antagonizes tumor necrosis factor-α–induced cell death145. NF-
κB also plays an important role in allergic inflammation146,147. Thus, it would be 
interesting to investigate whether H2S plays its anti-asthmatic role via sulfhydration 
of NF-κB. 
 
Development and maintenance of AHR in asthma depends on high eosinophil 
infiltration and TH2 cytokine production, particularly IL-13 and to a lesser extent IL-
4148-150. Thus enhanced TH2 cytokine production might also contribute to the observed 
higher AHR in KO-OVA mice. Our study and others have shown that H2S directly 
relaxes vascular smooth muscle by increasing KATP channel currents and 
hyperpolarizing membranes120,151. H2S can also relax nonvascular smooth muscle in a 
KATP channel-independent manner101,102. Chen et al101 have shown that exogenous 
NaHS directly relaxed airway smooth muscle pre-contracted with acetylcholine and 
potassium chloride, an effect that cannot be reversed by glybenclamide. In our study, 
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glybenclamide did not affect the inhibitory effect of exogenous H2S on OVA-induced 
AHR. Taken together, these data imply that H2S might reduce AHR in asthma models 
via two different avenues, i.e. relaxing airway smooth muscle in a KATP channel-
independent manner, and inhibiting TH2 cytokine production.  
 
Our animal asthma model in the current study is suitable for the study of acute 
inflammatory events in human asthma152, although it cannot mimic the chronic 
features of human asthma such as epithelial detachment, increased smooth muscle 
mass and peribronchial collagen deposit153. It would be intriguing to observe the 
effect of endogenous H2S on the development of airway remodeling during asthma 
with CSE-KO mice using an OVA-mouse model recently reported154. 
 
In summary, CSE is the main H2S-production enzyme in the mouse lung. CSE-
derived endogenous H2S is a protective factor against the development of asthma via 
inhibition of TH2 cytokines and eotaxin-1 secretion. Exogenous H2S supplementation 
suppresses asthmatic pathogenesis. These results establish, for the first time, a critical 
role of the endogenous CSE/H2S system in the development of allergic asthma, and 








Fig.3-1 OVA-challenge reduced CSE expression and H2S production in mouse 
lungs. OVA-sensitized WT and CSE-KO mice were challenged with OVA (WT-
OVA and KO-OVA). Sensitized mice challenged with saline were used as controls 
(WT-CON and KO-CON). Twenty-four hours after the last OVA-challenge, lung 
tissues were dissected for Western blot analysis (A) and H2S production detection 




                                                                        Figure 3-2 
 
 
Fig.3-2  CSE gene deficiency and asthmatic damage. A Increased AHR in KO-
OVA mice. Twenty-four hours after last OVA-challenge, AHR to inhaled 
methacholine (MCh) was measured by a resistance and compliance system. B Total 
and differential cell counts in BALF. BALF was recovered and total cell counts were 
determined after AHR measurement. Cytospins of leukocytes were stained with 
Wright-Giemsa and differential cell counts were performed for 200 cells. Eos, 
eosinophils; Ly, lymphocytes; Mac, macrophages; Neut, neutrophils. C 
Representative H&E staining of lung tissues. Scale bar: 100 µm. D–G Levels of IL-5, 
IL-13, IL-4, and eotaxin-1 in BALF were assessed by ELISA. For each group, 8 to 10 
mice were used. *P < 0.05. ND, not detected. 
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Appendix 1 NaHS treatments reversed OVA-induced AHR, airway 
inflammation, and cytokine levels in BALF in WT mice. OVA-sensitized WT 
mice were injected with 40 µmol/kg glibenclamide (Gly) i.p, plus 14 µmol/kg NaHS 
or vehicle (dimethyl sulfoxide) 30 minutes before and 8 hours after each OVA- 
challenge. Sensitized mice were challenged with saline as the control. A Decrease in 
OVA-induced AHR after NaHS treatment was not reversed by pretreatment with Gly. 
Twenty-four hours after the last OVA-challenge, AHR to inhaled methacholine 
(MCh) was measured by a resistance and compliance system. *P < 0.05 compared to 
WT-NaHS-OVA group; †P < 0.05 compared to WT-Gly-NaHS-OVA group. B Total 
and differential cell counts in BALF. After AHR measurement, BALF was recovered 
and total cell counts were determined. Cytospins of leukocytes were stained with 
Wright-Giemsa and differential cell counts were performed for 200 cells. Eos, 
eosinophils; Ly, lymphocytes; Mac, macrophages; Neut, neutrophils. C 
Representative H&E staining of lung tissues from the control group, and OVA-
challenged groups treated with vehicle, NaHS alone and Gly plus NaHS. Scale bar = 
100 µm. D–G Levels of IL-5, IL-13, IL-4, and eotaxin-1 in BALF were assessed by 
ELISA. For each group, 8 to 10 mice were used. *P < 0.05. 
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                                                                      Appendix 2 
  
Appendix 2  Reversal of asthmatic severity by NaHS supplementation in CSE- 
KO mice. OVA-sensitized CSE KO mice were given 14 µmol/kg NaHS (ip) or 
vehicle (ip) 30 minutes before and 8 hours after each OVA-challenge. A Decrease in 
OVA-induced AHR in CSE KO mice after NaHS treatment. Twenty-four hours after 
last OVA-challenge, AHR to inhaled MCh was measured with a resistance and 
compliance system. B Total and differential cell counts in BALF. After AHR 
measurement, BALF was recovered and total cell counts were determined. Cytospins 
of leukocytes were stained with Wright-Giemsa and differential cell counts were 
performed for 200 cells. Eos, eosinophils; Ly, lymphocytes; Mac, macrophages; 
Neut, neutrophils. C Representative H&E staining of lung tissues. Scale bar = 100 
µm. D Levels of IL-5, IL-13, IL-4, and eotaxin-1 in BALF. For each group, 8 to 10 
mice were used. *P < 0.05.  
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4. Chapter 4  
 
Early Onset of Allergic Asthma Due to Age-dependent Expressional Deficiency 
of Cystathionine gamma-lyase in Young Mice   
 
4.1 Abstract 
Allergic asthma is more prevalent in children than adults, an observation for 
which the pathogenic mechanisms remain unclear. We found that human umbilical 
cord blood mononuclear cells had lower levels of cystathionine gamma-lyase (CSE) 
proteins, the major endogenous H2S generating enzyme, than peripheral blood 
mononuclear cell from adult people. In animal models, we observed more severe 
allergic asthma with higher type-2 immunity in wild-type (WT) young mice than in 
old mice. This age-dependent propensity of immune reaction and asthma 
development resulted from lower levels of CSE expression and H2S production in 
young mice, and could be reversed by H2S supplementation. CSE gene knock-out 
(KO) mice had more severe asthma than WT mice but without the age-dependent 
asthma propensity. Lower endogenous CSE/H2S in young WT mice and in CSE-KO 
mice at all ages promoted the differentiation of splenocytes into type-2 helper T 
cytokines-generating cells, an effect that could be suppressed by H2S 
supplementation. H2S caused S-sulfhydration of GATA3 in spleen cells and 
decreased GATA3 nuclear translocation, leading to the inhibition of type-2 immunity. 
In conclusion, H2S suppresses allergen-induced type-2 immunity and the 
consequential asthma development. Lower activity of the CSE/H2S pathway in early 





Asthma is characterized by chronic airway inflammation and airway hyper-
responsiveness26,155. Although asthma can manifest at any age, the initiation of 
allergic sensitization and first asthmatic symptoms most often occur during the first 1-
3 years of life116,156, 32. Results from the Third National Health and Nutrition 
Examination Survey12 and a community-based birth cohort from Perth13 revealed that 
over 50% of asthma cases can be attributed to atopy. High incidence of atopic 
(allergic) asthma in children is closely associated with a type-2 helper T cell (TH2) 
biased immune response after birth8. TH2 response is essential for eliminating 
parasitic infections and for the development of atopic diseases, including asthma. TH2 
bias is evolved in utero to avoid maternal rejection47. After birth the neonatal immune 
system undergoes extensive development and gradually limits TH2 response. The 
kinetics of postnatal immune maturation process vary in human populations and an 
increased or prolonged bias towards TH2 response increases the risk of allergic 
asthma development50. For example, allergen-specific TH2 response, measured by 
cytokine mRNA levels in cord blood mononuclear cells, is greater than in peripheral 
blood mononuclear cells from one-year old infants. This age-related suppression of 
TH2 response is not observed in atopic children51, suggesting that their immune 
maturation lags behind non-atopic children. 
 
Early post-natal factors are critical for immune maturation and asthma development. 
Multiple cohort studies, including the current Canadian Healthy Infant Longitudinal 
Development (CHILD)157,158 and the Wayne County Health, Environment, Allergy, 
and Asthma Longitudinal Study, have showed various early life events (such as 
breastfeeding, growing up on farms or having pets) could protect against asthma 
development 57,159. The observed protective effects of these exposures are believed to 
be mediated through increasing early gut microbial colonization, which subsequently 
triggers the maturation of the developing neonatal immune system. This notion is 
supported by studies carried out on germ-free animals. These animals exhibited 
persistent TH2 biased response and were more likely to develop allergic asthma than 
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animals exposed to normal microbial flora64. Colonizing germ-free animals with 
Bacteroides fragilis induced maturation of their developing immune system and 
down-regulated splenic TH2 cytokine production64. Recent studies160, using novel 
high-throughput techniques, highlight the effects of gut bacterial colonization on 
systemic immune responses. Little is known, however, about how microbiota 
colonization in the gut suppresses systemic TH2 biased response in early childhood. 
 
CSE is one of the enzymes that produce H2S in mammalian tissues. CSE activity, 
assessed by cystathionine consumption, in cecum, colon, small intestine, kidney, 
liver, aorta, heart, and brain was lower in 11-12-week germ-free mice than in age-
matched non-germ-free mice106. Gut microbiota can up-regulate CSE 
activity/expression and endogenous H2S production via metabolic products in the 
colon104. For example, gut microbiota synthesize pyridoxal 5′-phosphate, the cofactor 
for CSE activation. CSE expression can also be upregulated by butyrate105, an end-
product of microbial fermentation of plant polysaccharides which cannot be digested 
by humans104. Products, such as IL-10, generated from the interaction between 
microbiota and the intestinal immune system, also promote CSE expression and H2S 
synthesis106.  
 
Gut microbiota is of low density and phylogenetic diversity after birth61,62. Successive 
colonization with Gram-positive cocci, Enterobacteria, Lactobacilli and 
Bifidobacteria happens in the first few weeks of life in mice and first few years of life 
in humans. This process can be accelerated by early life events such as breastfeeding, 
exposure to farms and pet ownership or delayed by other events such as caesarean 
section and antibiotic usage. Normally, by the age of 3-5 weeks in mice or 3-4 years 
in humans, gut microbiota becomes comparatively stable with adult-like diversity and 
population profile, although full development may take several more years in 
humans61,63. Consistent with the observations of germ-free animals and of lower 
microbiota colonization in human/animal infants, CSE activity and expression in 
mouse liver are very low after birth and increase gradually until reaching their peaks 
at 3 weeks of age118. CSE activity, reflected by cysteine formation rate, in the brain of 
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1 day old rats was 3 nmol/h/mg protein, but rose to 13 nmol/h/mg protein (near adult 
levels) by the second week161. In the preliminary study, we found that CSE 
expression in infant mouse lungs also increased gradually and reached its adult level 
by 12-16 weeks. Considering the stimulatory effect of microbiota on CSE expression 
in host organs and the time frame of microbiota colonization after birth, there appears 
to be a direct correlation between age-related colonization of microbiota and CSE 
expression in the host.  
 
The involvement of CSE/H2S in asthma development has been suggested in both 
human and animal studies. Plasma levels of H2S were lower in adult asthmatics and 
inversely related to the severity of asthma75. In allergic-asthma animal models (8-
week-old rats or 12-week-old mice), H2S levels in plasma and lung tissues were lower 
than in non-asthmatic control animals74. Exogenous H2S supplementation reduced 
asthma features induced by ovalbumin (OVA) challenges, including airway hyper-
responsiveness, eosinophil infiltration and elevated TH2 cytokine levels in 
bronchoalveolar lavage fluid (BALF). We hypothesize that the endogenous level of 
CSE/H2S is key in suppressing the biased TH2 response in early life and that age-
dependent changes in CSE/H2S levels underlie the high incidence of asthma at a 
young age.  
 
4.3 Results  
Age- and CSE-dependent allergic asthma development 
Allergic asthma was induced with OVA in young (3-4 weeks old) and old mice (7-8 
months old) (Fig. 4-1). OVA-sensitizations and challenges of young wild-type (WT) 
mice increased lung resistance by 351.1±85.2% and decreased lung dynamic 
compliance (Cdyn) by 58.2±6.4% in response to aerosolized methacholine (MCh) at 
12.5 mg/ml (Fig. 4-2 A). OVA-induced airway responsiveness was much weaker in 
old WT mice than in young WT mice with only a 170.4±50.6% increase in lung 
resistance and 39.0±5.9% decrease in Cdyn, respectively (Fig. 4-2 A). OVA-
challenge-induced BALF inflammatory cell influx, especially by eosinophils, was 
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approximately 2 times more in young WT mice than in old WT mice (Fig. 4-2 B). 
The IL-4 level in BALF from young WT mice was also higher than in BALF from 
old WT mice (Fig. 4-3 A). Similar patterns of elevation were seen with IL-5 and 
eotaxin in young WT mice, although not as pronounced as IL-4 (Fig. 4-3 A). 
Histological analysis of lung tissues showed more peribronchial and perivascular 
inflammatory infiltrates in young WT mice than in old WT mice (Fig. 4-3 B and Fig. 
4-4). Thus, allergen exposure at a young age induces more severe allergic asthma 
symptoms than the same exposure at an older age. 
 
OVA-treated young and old CSE-KO mice responded similarly to MCh challenges 
with airway resistance increasing by 712.6±85.9% and 661.8±92.6% and Cdyn 
dropping by 74.9±3.5% and 80.3±2.1%, respectively  (Fig. 4-2 A). After OVA-
challenges young and old CSE-KO mice had comparable inflammatory cell 
infiltration in their airways and TH2 cell cytokine levels (IL-4, IL-5 and IL-13) in 
BALF (Fig. 4-2 B and Fig. 4-3 A). Extensive inflammation was seen in lung tissues 
from young and old CSE-KO mice (Fig. 4-3 B). Airway hyper-responsiveness and 
inflammation were more severe in CSE-KO mice than in WT mice of the same age. It 
is clear that the elimination of CSE expression abolished age-related asthma 
susceptibility and worsened allergic asthma at all ages. 
 
CSE expression levels and immunoreactions in OVA-sensitized mice 
To correlate expression levels of H2S-generating enzymes with TH2 cytokine 
production, we isolated mouse mediastinal lymph cells and splenocytes 5 days after 
OVA-sensitization and then re-stimulated these cells in vitro with OVA for 3 days. A 
previous study showed that an OVA-specific T cell response appeared in mediastinal 
lymph nodes and spleens 4 days after systemic OVA immunization (ip)162. Lymph 
cells and splenocytes from old WT mice produced less IL-4, IL-5 and IL-13 after 
OVA-re-stimulation than those from young WT mice (Fig. 4-5 A & B). No such 
difference was observed between young and old CSE-KO mice (Fig. 4-5 A & B). The 
cells from CSE-KO mice generated more TH2 cytokines than the cells from WT mice 
of the same age. Splenocytes from young WT mice had much lower abundance of 
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CSE proteins than did splenocytes from old WT mice (Fig. 4-6 A). Expression of the 
other two H2S-generating enzymes, 3-mercaptopyruvate sulfurtransferase (MST) and 
cystathionine β-synthase (CBS), was also examined. MST protein levels were 
comparable in splenocytes from young and old WT mice (Fig. 4-6 C). CBS proteins 
were undetectable in both groups (Fig. 4-6 C). Splenocytes from young WT mice 
generated less H2S than did splenocytes from old WT mice (Fig. 4-6 B). The same 
pattern was observed in human samples. CSE proteins, but not CBS or MST proteins, 
were detected in human spleen tissue (Fig. 4-6 D). Peripheral blood mononuclear 
cells (PBMC) from human adults (38-55 years old) had more CSE proteins than 
umbilical cord blood mononuclear cells (CBMC) (Fig. 4-6 D). Neither PBMC nor 
CBMC expressed CBS proteins. Low abundance of MST proteins was detected in 
PBMC (Fig. 4-6 D).  
 
To test whether the observed effects of CSE deficiency were due to endogenous H2S 
deprivation, we administered NaHS (14 µmol/kg ip twice daily) to mice beginning 
two days prior to OVA-sensitization and continuing until two days after sensitization 
(Fig. 4-1). At the end of this NaHS treatments regime, the mice were sacrificed and 
mediastinal lymph cells and splenocytes were isolated. NaHS treatment significantly 
reduced OVA-re-stimulation-induced IL-4, IL-5 and IL-13 production in lymph cells 
and splenocytes from both young WT mice and CSE-KO mice at all ages, with IL-4 
being decreased most dramatically (Fig. 4-7 A & B). In old WT mice, NaHS only 
slightly, though significantly, decreased IL-4 level in splenocytes but failed to do the 
same in lymph cells. In the same groups of cells from old WT mice, NaHS increased 
IL-5 and decreased IL-13 production in splenocytes. However, it decreased both IL-5 
and IL-13 production in lymph cells. It is reasoned, therefore, that the type-2 
immunity modulating effect of CSE was mediated by H2S, and that exogenous H2S 
treatment was more efficient in suppressing type-2 immunity when endogenous H2S 
level was minimal. 
 
In another group of mice, the animals were not sacrificed after NaHS treatments 
regime as described above. Instead, they were kept for another two weeks during 
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which time they were challenged with OVA on day 21 to 23 to establish asthma 
models (Fig. 4-1). NaHS treatments significantly alleviated OVA-challenge-induced 
airway resistance to MCh by 1.6 times in young WT mice and about 2 times in young 
and old CSE-KO mice compared with saline-treatments  (Fig. 4-8 A). NaHS-treated 
young WT mice and young/old CSE-KO mice exhibited less airway inflammatory 
cell infiltration after OVA-challenges compared with saline-treated mice, mainly due 
to fewer eosinophils and neutrophils in the lung (Fig. 4-8 B). TH2 cytokines IL-4 and 
IL-5 in BALF also decreased in NaHS-treated young WT mice and young/old CSE-
KO mice (Fig. 4-9 A). Consistent with BALF cell counting, fewer peribronchial and 
perivascular inflammatory cells were present in lung tissues of NaHS-treated young 
WT mice and young/old CSE-KO mice (Fig. 4-9 B). Negligible changes in airway 
responsiveness and inflammatory infiltration were seen in NaHS-treated old WT mice 
in comparison with saline-treated mice (Fig. 4-8 and Fig. 4-9). These data suggest 
that when the functionality of CSE/H2S system is compromised, NaHS treatments 
during sensitization phase have a protective effect against the development of ensuing 
allergic asthma. 
 
H2S-induced inhibition of naïve immune cell differentiation in vitro 
To explore the mechanisms by which H2S modulates immune response, splenocytes 
were cultured in vitro under the conditions for T cell differentiation into TH2 
cytokine-generating cells (see section 2.12). The differentiated cells were stimulated 
for 24 hours with PMA/ionomycin to generate cytokines. Old WT mouse splenocytes 
produced less IL-4, IL-5 and IL-13 than young WT mouse splenocytes (Fig. 4-10 A). 
Old CSE-KO mouse splenocytes generated IL-4 and IL-5 in amounts similar to young 
CSE-KO mouse splenocytes (Fig. 4-10 A). The amounts of IL-4, IL-5 and IL-13 
generated by CSE-KO mouse splenocytes were greater than those generated by WT 
mouse splenocytes (Fig. 4-10 A). NaHS treatments during the differentiation culture 
suppressed TH2 cytokine generation in CSE-KO mouse splenocytes, in a 
concentration-dependent manner (Fig. 4-10 B). 
 
Since some of the cellular protection effects of H2S are mediated by its anti-oxidant 
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effect163,164,165, H2S might suppress type-2 immunity by inhibiting production of 
reactive oxygen species (ROS). However, anti-CD3 stimulation-induced ROS 
production in splenocytes did not vary with endogenous H2S level (Fig. 4-11).  
 
Activation of signal transducer and activator of transcription factor-6 (STAT6) is 
critical for antigen-induced TH2 cytokine production and naïve T cell 
differentiation166. STAT6 can be activated by two key TH2 type cytokines, IL-4 and 
IL-13, through the shared subunit IL-4Rα of their cognate receptors167. Mouse 
splenocytes with different endogenous H2S levels were treated with IL-4 (50 ng/ml) 
for 1 hour. Splenocytes from WT and CSE-KO (young and old) mice had comparable 
levels of total STAT6 proteins. IL-4 induced phosphorylation of STAT6 was also 
comparable among these four groups of mice (Fig. 4-12 A). NaHS treatments did not 
alter STAT6 phosphorylation in IL-4-treated young CSE-KO mouse splenocytes (Fig. 
4-12 B). Therefore, the CSE/H2S-induced inhibition of type-2 immune response is not 
mediated by STAT6. Instead, GATA3 surfaced as the main molecular target of H2S. 
GATA3 is the final mediator of many signal pathways in regulating innate and 
adaptive type-2 immunity168,169. It selectively induces TH2 cytokine production and 
inhibits TH1 differentiation170. We assessed nuclear GATA3 expression in 
splenocytes cultured under the conditions favoring T cell differentiation into TH2 
cytokine-generating cells. Nuclear GATA3 protein levels were much higher in 
differentiated splenocytes from young WT mice than in those from old WT mice. 
Differentiated splenocytes from young and old CSE-KO mice expressed similar 
levels of nuclear GATA3 proteins, levels higher than those from WT mouse 
splenocytes (Fig. 4-12 D). NaHS treatments during differentiating culture decreased 
nuclear GATA3 expression in young CSE-KO mouse splenocytes in a concentration-
dependent manner (Fig. 4-12 E). To minimize potential interference of endogenous 
H2S on NaHS effects, only CSE-KO splenocytes were used in the experiments 
described in Fig. 4-10 B, Fig. 4-12 B and Fig. 4-12 D. 
 
H2S-induced GATA3 S-sulfhydration 
One of the molecular mechanisms for H2S-induced post-translational modification of 
 64 
proteins is S-sulfhydration where cysteine-SH groups are converted to –SSH122. S-
sulfhydrated GATA3 protein levels were significantly greater in spleens from old WT 
mice than in those from young WT mice, whereas the sulfhydrated GATA3 levels in 
young/old CSE-KO mouse spleens were much lower than in WT spleens (Fig. 4-13 
A). In HEK-293 cells with heterologous overexpression of CSE, GATA3 S-
sulfhydration was remarkably decreased by CSE inhibitor dl-propargylglycine (PPG, 
1 mM) and increased by NaHS (30 µM) treatments (Fig. 4-13 B). Site-directed 
mutagenesis revealed that GATA3 was S-sulfhydrated at cysteine 84, 182, and 248 
(Fig. 4-13 C). Double mutation of cyteine-84/182 (GATA3-C84/182) or cysteine-
84/248 (GATA3-C84/248) decreased endogenous H2S as well as NaHS induced S-
sulfhydration of GATA3 proteins (Fig. 4-14 A). The ratio of nucleus/cytosol GATA3 
level was higher with mutated GATA3 than with wild-type GATA3 (Fig. 4-14 B), 
suggesting that S-sulfhydration of GATA3 decreases its nuclear translocation. 
 
We also tested the effect of CSE expression on TH1 cell differentiation. Splenocytes 
were cultured under TH1 differentiation condition (plate-bound anti-mouse CD3ε, 
anti-mouse CD28, mouse IL-12, mouse IL-2, and anti-mouse IL-4) and then re-
stimulated with PMA/ionomycin for 72 hours to generate IFN-γ. Splenocytes from 
old WT mice generated more IFN-γ than those from young WT mice (Fig. 4-15 A). 
CSE-KO mouse splenocytes produced less IFN-γ than WT mouse splenocytes (Fig. 
4-15 A). On the other hand, NaHS increased IFN-γ production only at the highest 
concentration used in this study (30 µM) (Fig. 4-15 B).  
 
TH1 cytokine IL-12 and T-box protein (T-bet) are essential for the initiation and 
maintenance of the TH1 response. By binding to IL-12R, IL-12 activates TH1-specific 
transcription factor STAT4, leading to more IFN-γ production and T-bet expression. 
T-bet controls TH1 differentiation by directly inducing IFN-γ and IL-12Rβ2 chain 
gene transcription as well as repressing TH2 lineage commitment171. CSE deficiency 
led to lower nuclear levels of T-bet in differentiated splenocytes from young WT and 
young/old CSE-KO mice (Fig. 4-15 E). NaHS (30 µM) treatment, again, increased 
nuclear T-bet levels (Fig. 4-15 F). IL-12-induced STAT4 phosphorylation172, which 
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initiates the differentiation of naïve T cells into TH1 cells, was not affected by H2S 
(Fig. 4-15 C & D). Our observation is consistent with an earlier report173, in which 
blocking CSE activity by dl-propargylglycine delayed heart allograft rejection and 




Immune immaturity in early childhood favors type-2 dominant effector and memory 
responses to harmless antigens. This renders children more susceptible to developing 
allergic asthma174,175. Our study found that CSE expression in lymph cells played a 
key role in suppressing TH2 response; its deficiency contributed to greater type-2 
immunity and consequent asthma development in early life. CSE expression levels in 
splenocytes from young mice and neonatal human CBMC are significantly lower than 
those in splenocytes from old mice and adult human PBMC. Antigen immunization 
primes immune cells with low CSE for preferential TH2 cytokines expression: OVA-
sensitization of young WT mice resulted in more TH2 cytokine-generating cells in 
peripheral lymph tissues, including mediastinal lymph nodes and spleens, than in old 
WT mice. This result is consistent with clinical observations that link early life 
sensitization with augmented TH2 cytokine responses and adverse asthma outcome45. 
Such age-dependent differences were not observed in CSE-KO mice in which CSE 
expression is eliminated. OVA-sensitization induced comparable TH2 responses in 
young and old CSE-KO mice. The elevated TH2 response in peripheral lymph tissues 
evoked more dramatic inflammation and asthmatic symptoms in OVA-immunized 
WT young mice when they were re-exposed to aerosol OVA-challenges. Asthma 
development in young and old CSE-KO mice, on the other hand, was comparable. 
These data suggest that the age-related changes in CSE expression in lymph systems 
during immune sensitization controlled the OVA-induced immune response and 
consequent asthma development. 
 
The immune-modulating effect of CSE is mediated mainly through H2S, an important 
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gasotransmitter. H2S can up-regulate CD11b and G protein-coupled receptor kinase 2 
in neutrophils and improve their migration and survival in sepsis induced by cecal 
ligation and puncture80. Nanomolar concentrations of H2S potentiate T lymphocyte 
activation in vitro. Our current study showed that H2S was also responsible for the 
observed protective effect of CSE against asthma development79. Administering 
NaHS during the sensitization phase significantly alleviated OVA-induced TH2 
priming in peripheral lymph tissues and prevented subsequent asthma development.  
 
TH2 cytokines play critical roles in the development of allergic asthma 176. IL-4, and 
to a lesser extent IL-13, promote IgE production, which subsequently binds to its 
high-affinity receptors on basophils and mast cells. These effector cells release 
cytokines, chemokines, histamine, heparin, serotonin and proteases, resulting in 
airway smooth muscle constriction, inflammatory cell infiltration, etc. IL-5 is critical 
for the maturation, differentiation and migration of eosinophils. IL-13 stimulates 
mucus production by goblet cells and airway hyper-responsiveness. After TH2 
polarizing culture, splenocytes from old WT mice secreted much lower levels of TH2 
cytokines than splenocytes from young WT mice. Consistent with our results of in 
vivo OVA-sensitization (Fig. 4-4 A&B), CSE-KO splenocytes showed no age-
dependent differences in their TH2 cytokine-generating abilities when polarized in 
vitro. NaHS treatments, in a concentration-dependent manner, suppressed TH2 
cytokine generation in young CSE-KO mouse splenocytes cultured under TH2 
polarization conditions. Clearly, the levels of CSE proteins and H2S production in 
splenocytes decisively affect their differentiation toward TH2-generating cells.  
 
The genes of TH2 cytokines are clustered on human chromosome 5 and mouse 
chromosome 11177. Multiple signal pathways modulate their expression. IL-4-induced 
STAT6 phosphorylation is a critical early signal in inducing TH2 cytokine 
expressions178. By binding to type-I IL-4R, IL-4 activates janus kinase 1 and 3, and 
subsequently phosphorylates STAT6. The phosphorylated STAT6 translocates into 
nucleus and binds to its targeted DNA sequences such as the promoter of TH2 master 
regulator - GATA3. CSE/H2S-induced inhibition of type-2 immunity is not mediated 
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by STAT6 activation. Instead, our data showed that H2S inhibited asthma 
development by S-sulfhydrating GATA3 so that its nuclear translocations were 
lessened (Fig. 4-14 C). GATA3 is expressed in naïve CD4+ T cells and is upregulated 
dramatically during TH2 differentiation via both IL-4-STAT6-dependent and -
independent signaling pathways179. GATA3 regulates chromatin modification at the 
TH2 cytokine locus by binding to regulatory elements such as conserved non-coding 
sequence (CNS)-1, hypersensitive site V (HSV)/CNS2, intronic enhancer (IE)/HSII 
and conserved GATA3 response element (CGRE). GATA3 also binds directly to Il-5 
and Il-13 promoters. GATA3-deficient CD4+ T cells fail to differentiate into TH2 cells 
even when the cells are cultured under TH2-skewing conditions180. Overexpression of 
GATA3 in developing TH1 cells, on the other hand, can lead to TH2 cytokine gene 
expressions.  
 
There are 12 cysteine residues in human and mouse GATA3 (Fig. 4-16). They are 
conserved between humans and mice. Eight out of 12 cysteine residues locate in the 
zinc finger region which cannot normally be modulated (Fig. 4-16, green frames). 
Among the remaining 4 cysteine residues (Fig. 4-16, red frames), H2S can S-
sulfhydrate three cysteine residues (C84, C182 and C248) (Fig. 4-13 C).  
 
GATA3 contains nuclear localization sequence (NLS) which facilitates its nuclear 
translocation by binding to nuclear import protein importin-a181. Malik et al. found 
that S-Nitrosylation of chloride intracellular channel protein (CLIC4) enhanced its 
association with importin-a182. CD spectra analysis and trypsinolysis of the modified 
protein suggested this enhancement was likely due to structure change of CLIC4 
protein caused by S-nitrosylation182. C248 of GATA3 locates at the very beginning of 
NLS (Fig. 4-16, yellow frames). Thus, it is very possible that S-sulfhydration of C84, 
C182 and C248 alters the structure of GATA3 and the affinity of the importin-a–NLS 
interaction. Double mutation of cyteine-84/182 or cysteine-84/248 decreased GATA3 
S-sulfhydration level and increased its nuclear expression. Considering the important 
role of GATA3 in the initiation and maintenance of type-2 response, our results 
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suggest a novel and critical mechanism for the protective effect of H2S against 
asthma.  
 
Another feature of the immature immune system in childhood is the absence of strong 
protective TH1 polarizing signals. TH1 cells produce IFNγ and are essential to repel 
intracellular pathogens. Defective TH1 response is associated with more severe virus 
infections and atopy 183. TH1 cells from young mice and infants have limited IL-12 
and IFN-γ-releasing capacity184. The Protection against Allergy—Study in Rural 
Environments (PASTURE) showed high allergen-specific IgE concentrations in cord 
blood related to decreased IFN-γ levels53. Other epidemiologic studies also suggest an 
inverse association between IFN-γ levels and atopy185; a positive correlation of total 
IgE levels with IL-4, IL-5 and IL-13 levels186. TH1 cytokines and T-bet inhibit TH2 
responses by suppressing the expressions of GATA3 and TH2 cytokine genes. Thus, 
upregulating TH1 responses in early life can restore the TH1/TH2 balance and promote 
tolerance to aeroallergens. Our study found that upregulated CSE/H2S in old WT 
mice favors TH1 differentiation by promoting nuclear T-bet expression. Although less 
robust than its effects on suppressing TH2 cytokines production, exogenous H2S 
facilitated IFN-γ production. Limited intestine microbiota diversity is associated with 
weak TH1 response during the first 2 years of life 61, an effect that might be mediated 
by the low expression of CSE/H2S at a young age. 
 
Susceptibility to asthma is also associated with defects in the airways. Airway smooth 
muscle cells (ASMCs) are the final effecters in controlling airway contraction, and 
their hyper-responsiveness in early life increase the risk of asthma in childhood97,98. 
In addition to its contractile properties, ASMCs secrete a wide variety of 
inflammatory mediators during asthma progression.  These mediators activate and 
recruit T cells, mast cells, neutrophils, and eosinophils187. Both the number and size 
of ASMCs are increased in children with asthma188. We confirmed CSE expression in 
human lung samples (Fig. 4-17 A) and found that CSE expression in WT mouse lung 
increased with age (Fig. 4-17 B). Our previous studies showed that CSE was 
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expressed in mouse ASMCs and vascular smooth muscle in mouse lungs74,137. In the 
current study we found that airway CSE expression increased in an age-dependent 
manner, an observation not apparent with CBS or MST (Fig. 4-18). In the absence of 
allergen exposure, airway responsiveness to MCh challenge (12.5 mg/ml) of young 
WT mice and young/old CSE-KO mice, was more than two times higher than that of 
old WT mice (Fig. 4-19). H2S is known to relax ASMCs by opening the KATP 
channel189 or inhibiting Ca2+ release through inositol-1,4,5-trisphosphate (InsP3) 
receptors102. Therefore, low abundance of CSE in young mice might alter intrinsic 
properties of ASMCs and lead to airway hyper-responsiveness because of decreased 
endogenous H2S production. H2S also affects the immunomodulatory function of 
ASMCs by inhibiting their release of pro-inflammatory mediators such as IL-873 or 
upregulating anti-inflammatory mediators such as prostaglandin E190. Sufficient 
CSE/H2S in ASMCs likely allows old WT mice to exert a 'braking' effect on local 
inflammation and ASMC constriction during allergen exposures. These local effects 
of H2S in the lung explain the therapeutic effect of NaHS treatment during the OVA-
challenge phase as shown in previous studies74,191. NaHS treatment in the OVA-
challenge phase decreased IL-5 and IL-13 levels in BALF of both WT and CSE-KO 
mice191. This effect is more likely due to inhibited migration of leukocytes to the lung 
rather than to inhibited TH2 cytokine generation in effector lymphocytes; NaHS 
treatment suppressed TH2 cytokines generation from established effector cells only at 
50 µM or higher concentrations68.  
 
During OVA-sensitization, primary TH2 response is initiated; naïve T cells 
differentiate into TH2 cells. In the OVA-challenge phase, a secondary TH2 response 
occurs; differentiated memory TH2 cells proliferate and migrate to the lung and 
airways where asthmatic reactions develop. Thus H2S acts mainly on lymphocyte 
differentiation in the OVA-sensitization phase whereas in the OVA-challenge phase, 
altered H2S metabolism targets the airways. At these different phases, independently 




In conclusion, endogenous H2S production in the lung and peripheral lymph tissues 
suppresses allergen-induced type-2 immunity and consequent asthma development. 
Lack of endogenous H2S due to lower CSE abundance in early development may 
explain the higher incidence of allergic asthma in children. This discovery sheds light 





Fig. 4-1 Experimental protocol for establishing OVA-induced mouse allergic 
asthma. AHR, airway hyper-responsiveness; ip, intra-peritoneal injection. µg/g, µg 
per gram body weight.  
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Fig. 4-2 CSE deficiency increased airway hyper-responsiveness and airway 
inflammatory infiltrates in OVA-induced mouse allergic asthma model. A 
Changes in mouse airway responsiveness, measured as airway resistance and 
compliance (Cdyn) with increasing doses of methacholine. WT-y: wide-type young 
mice; WT-o: wide-type old mice; KO-y: CSE-knockout (KO) young group; KO-o: 
CSE-KO old group. B Changes in the total cell numbers, macrophages (Mac), 
eosinophils (Eos), neutrophils (Neut) and lymphocytes (Lymph) in bronchoalveolar 
lavage fluid (BALF). The results in WT-y, WT-o, KO-y and KO-o were generated 
from 12, 10, 15 and 12 animals, respectively. Statistical significance was determined 
with two-way ANOVA. * P< 0.05 for WT-young compared with WT-old mice; # P 






Fig. 4-3 CSE deficiency increased type-2 cytokines in BALF and severity of 
asthma in OVA-induced mouse allergic asthma model. A Changes in different 
cytokine levels in BALF. B Representative H&E-stained mouse lung tissues. Scale 
bars, 200 µm. The results in WT-y, WT-o, KO-y and KO-o were generated from 12, 
10, 15 and 12 animals, respectively. Statistical significance was determined with two-
way ANOVA. * P< 0.05 for WT-young compared with WT-old mice; # P <0.05 for 





Fig. 4-4 Increased numbers of peribronchial eosinophils in OVA-treated mice. 
Total eosinophils from 7 different bronchi in each H&E-stained mouse lung slide 
were counted. Slides from 3-4 different mice were counted for each group. * P<0.05 
for WT-young mice compared with WT-old mice; # P<0.05 for CSE-KO mice 







Fig. 4-5 CSE/H2S suppressed OVA-sensitization-induced differentiation of 
mediastinal lymph cells and splenocytes.  A-B Changes in cytokine levels in the 
culture media of mediastinal lymph cells and splenocytes (ELISA). Mediastinal 
lymph nodes and spleens were collected 5 days after OVA-sensitization from 6 mice 
per group. Isolated mediastinal lymph cells (A) and splenocytes (B) were then re-
stimulated in vitro with OVA for 3 days. Differences among WT-young, WT-old, 
KO-young and KO-old groups were determined by two-way ANOVA test. *P < 0.05 
for WT-young mice compared with WT-old mice; #P <0.05 for CSE-KO mice 






Fig. 4-6 The expression of H2S generating enzymes in mouse and human 
samples.  A CSE protein levels in splenocytes (n=4). B H2S generated by cultured 
splenocytes (n=4). C CBS and MST protein levels in splenocytes. D CBS, CSE and 
MST protein levels in human cord blood mononuclear cells (CBMC, n=5), human 
peripheral blood mononuclear cells (PBMC, n=6) and a human spleen sample (n=1). 









Fig. 4-7 H2S supplementation suppressed OVA-sensitization-induced 
differentiation of mediastinal lymph cells and splenocytes. A-B Relative levels of 
cytokines in the culture medium of mouse mediastinal lymph cells (A) and mouse 
spleen cells (B), measured with ELISA. Mean cytokine levels of control groups are 
set as 100%. Comparison between control group and NaHS-treatment group was 









Fig. 4-8 NaHS treatment significantly reduced OVA-induced airway hyper-
responsiveness and inflammatory infiltrates in CSE-KO mice and WT young 
mice. A Relative airway resistance and Cdyn of mice with or without NaHS 
treatment. Mean resistance and mean Cdyn values of respective control groups are set 
as 100%. B Relative total cell numbers, macrophages (Mac), eosinophils (Eos), 
neutrophils (Neut), and lymphocytes (Lymph) in BALF. The average numbers of 
total cells, macrophages, eosionophils, neutrophils and lymphocytes in BALF from 
respective control groups are set as 100%.  Comparison between control and NaHS-






Fig. 4-9 NaHS treatment significantly reduced OVA-induced type-2 cytokine 
production and alleviated asthma severity in CSE-KO mice and WT young mice. 
Relative cytokine levels in BALF from the mice with or without NaHS treatment. 
Mean cytokine levels of respective control groups are set as 100%. D Representative 
H&E-stained lung tissues of NaHS-treated mice. Scale bars, 200 µm. The results in 
each group were collected from 6 animals. Comparison among control and NaHS-
treatment group was made using unpaired t-test. *P <0.05 for NaHS-treatment group 
compared with control group. 
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Fig. 4-10 Endogenous and exogenous H2S reduced the differentiation of 
splenocytes into TH2 cytokine-generating cells in vitro. A-B IL-4, IL-5 and IL-13 
levels in the culture medium of splenocytes cultured in (A) the absence or (B) the 
presence of NaHS in various concentrations (see section 2.12). IL-4, IL-5 and IL-13 
levels in the culture medium of splenocytes. Mean cytokine levels of NaHS-0 µM 
groups in (B) are set as 100%. Only CSE-KO-young splenocytes were used in (B) to 
minimize the potential interference of endogenous H2S on NaHS effects. Differences 
among WT-young, WT-old, CSE-KO-young and CSE-KO-old groups were 
determined with two-way ANOVA in (A). Comparisons among different NaHS-
treatment conditions in (B) were made using one-way ANOVA (followed by Dunnett 
post test). *P < 0.05 for WT-young mice compared with WT-old mice and for NaHS-
treatment group compared with NaHS-0 µM group; # P <0.05 for CSE-KO mice 









Fig. 4-11 Levels of reactive oxygen species (ROS) in spleen cells with or without 
anti-mouse CD3ε treatment. Splenocytes isolated from WT-young, WT-old, CSE-
KO-young, and CSE-KO-old mice were cultured for 24 hours in the absence or 
presence of plate-bound anti-mouse CD3ε. ROS generated in splenocytes were 
measured using Abcam's DCFDA - Cellular Reactive Oxygen Species Detection 








Fig. 4-12 The effect of CSE/H2S system on STAT-6 and GATA3 pathways. A and 
B IL-4-treatment-induced STAT6 phosphorylation in splenocytes (n=3 for each 
group). C and D Nuclear and cytosolic GATA3 expression in differentiated 
splenocytes (n=4 for each group). Only CSE-KO-young splenocytes were used in (B 
and D) to minimize the potential interference of endogenous H2S on NaHS effects.  
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                                                      Figure 4-13 
 
Fig.4-13 S-sulfhydration of GATA3. A Endogenous S-sulfhydration of GATA3 in 
mouse spleen tissues (n=4 for each group). B S-sulfhydration of GATA3 in HEK-293 
cells with over-expressed CSE (n=3 for each group). PPG is dl-propargylglycine. C 
S-sulfhydration of GATA3 and its mutants heterologously expressed in HEK-293 
cells. Four GATA3 cysteine residues (C84, C182, C248, and C375) were mutated 
into serines. S-sulfhydration of these mutants was tested with or without NaHS (10 
µM) treatment. Differences among WT-young, WT-old, CSE-KO-young and CSE-
KO-old groups in (A) were determined by two-way ANOVA. Comparisons among 
different treatment conditions in (B) were made using one-way ANOVA followed by 
Dunnett post test. *P <0.05 when WT-young mice compared with WT-old mice, and 
for NaHS/PPG/PPG+NaHS compared with the control group in (B), # P <0.05 for 
CSE-KO mice compared with WT mice in (A).  
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                                                      Figure 4-14 
 
Fig.4-14 S-sulfhydration of GATA3 reduced its nuclear translocation.  A S-
sulfhydration of GATA3 with double mutations of C84/C182 or C84/C248 in HEK-
293 cells. In these mutants, the targeted cysteines were replaced by serines. B Double 
mutation of C84/C182 or C84/C248 increased GATA3 nuclear expression in HEK-
293 cells (n=4 for each group). C Proposed mechanisms for the CSE/H2S pathway at 
different ages in the development of allergic asthma. Eos: eosinophils, Mac: 
macrophages, Lym: lymphocytes. Greater severity of asthma in young WT mice 
(compared to old WT mice) can be explained by the age-dependent CSE/H2S 
expression pattern in splenocytes. Lower levels of CSE proteins and H2S in 
splenocytes from the young WT mice cause decreased S-sulfhydration of GATA3, 
increasing its nuclear translocation. This promotes the differentiation of splenocytes 
into TH2 cytokine-generating cells and the development of more severe asthma. *P 
<0.05.  
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                                                      Figure 4-15 
 
 
Fig. 4-15 Endogenous and exogenous H2S enhanced the differentiation of 
splenocytes into IFN-γ-generating cells in vitro. A-B IFN-γ levels in the culture 
media of splenocytes. Mean IFN-γ level of NaHS-0 µM group in (B) is set as 100%. 
C-D IL-12-treatment induced STAT4 phosphorylation in splenocytes. E-F Nuclear 
and cytosolic T-bet expression in splenocytes. *P < 0.05 for WT-young compared 
with WT-old mice and for NaHS-30 µM group compared with NaHS-0 µM group; # 
P <0.05 for CSE-KO mice compared with WT mice.   
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                                                Figure 4-16 
 
 
Fig. 4-16 Alignment of protein sequences of human and mouse GATA3. Eight of 
the 12 cysteine residues of GATA3 locate in the zinc figure region (green frames). 
The remaining 4 cysteine residues of GATA3 are shown with red frames. The nuclear 
localization sequence of GATA3 is indicated with yellow frames.
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                                                                                                                 Figure 4-17 
 
 
Fig. 4-17 CSE-expression levels in lung tissue from humans and WT mice. A 
CBS, CSE, and MST protein levels in human lung tissue. B CSE protein levels in 
lung tissues of WT mice at different ages (4-week, 8-week and 16-week-old) (n=4 for 
each group). *P<0.05 for both 8- and 16-week old WT mice compared with 4-week-
old WT mice. 
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                                                                Figure 4-18 
 
 
Fig. 4-18 The protein levels of H2S-generating enzymes in WT mice airways. The 
tracheas and lung tissues of WT mice at different ages (4-week, 8-week and 15-week-
old) were removed immediately after the animals were euthanized. Lung parenchyma 
was carefully removed until only the bronchial tree and trachea remained. CBS, CSE, 
and MST expression levels in the bronchial tree and trachea were tested by Western 
blot (n=4 for each group). * P<0.05 for both 8- and 15-week old WT mice compared 
with 4-week-old WT mice. 
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                                                                  Fig. 4-19 
 
Fig. 4-19 Airway responsiveness and histological features of mice without 
asthma. A Airway responsiveness was measured as airway resistance and 
compliance (Cdyn) using increasing concentrations of methacholine. B 
Representative H&E-stained mouse lung tissues. Scale bars, 200 µm. WT-y: WT 
young mice; WT-o: WT old mice; KO-y: CSE-KO young mice; KO-o: CSE-KO old 
mice.                                                                     
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5. Chapter 5 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
A sharp increase has been seen in the global prevalence, morbidity, mortality, and 
economic burden associated with asthma over the last 40 years. The greatest rise in 
asthma prevalence has been in children. Challenges in asthma management include 
understanding the cellular and molecular mechanisms for asthma, practical methods 
for early detection, monitoring symptoms and predicting prognosis, and the need for 
novel therapeutic approaches with improved efficacy and selectivity. 
 
In previous studies we showed that H2S at 1-3 mM relaxes tracheae in vitro. The 
studies of Fitzgerald, et al. and Castro-Piedras et al. suggest this H2S effect might be 
mediated by opening KATP channel189 or inhibiting Ca2+ release through InsP3 
receptors102. Our current in vivo study further highlighted the importance of CSE/H2S 
in modulating airway responsiveness (chapter 3). CSE deletion, which led to an 81% 
reduction of endogenous H2S production in the lung, aggravated OVA-induced 
airway hyper-responsiveness in CSE-KO mice, while H2S supplementation lowered 
OVA-induced airway hyper-responsiveness in both WT and CSE-KO mice. Besides 
relaxing vascular smooth muscle directly  (by increasing KATP channel currents and 
hyperpolarizing membranes), H2S may also reduce airway hyper-responsiveness by 
inhibiting TH2 cytokine production. TH2 cytokines, particularly IL-13 and L-4148-150, 
augment stimulant-induced calcium influx and contractile responses in airway smooth 
muscle cells.  
 
CSE deficiency aggravated OVA-induced TH2 cytokines and eotaxin-1 production, 
leading to more eosinophil infiltration in the lungs of CSE-KO mice. Exogenous H2S 
supplementation significantly decreased OVA-induced BALF cytokines as well as 
reducing eosinophilic airway inflammation in both WT and CSE-KO mice. These 
results suggest that both endogenous and exogenous H2S protect against the 




It is known that the incidence of allergic asthma is age-dependent; most asthma 
begins during the preschool years. Structural and functional changes of asthma 
(including bronchial hyper-responsiveness, reticular basement membrane thickening 
and eosinophilic inflammation) start to develop between 1 and 3 years of age192. This 
places childhood asthma as the major target for primary prevention. Childhood 
asthma is usually studied separately because biomarkers and treatment strategies for 
adult asthmatics are not always applicable in children.  
 
To investigate whether CSE/H2S is involved in the development of childhood asthma, 
allergic asthma was induced with OVA in young (3-4 weeks old) and old (7-8 months 
old) mice. With this model, we demonstrate in chapter 4 that spleen and airway CSE 
expression, but not CBS or MST expression, increased with age. Lower levels of CSE 
expression and H2S production in the spleens of young mice amplified the type 2 
response towards antigens: OVA-sensitization of young WT mice resulted in more 
TH2 cytokine-generating cells in peripheral lymph tissues with higher ensuing TH2 
cell cytokine levels (IL-4, IL-5 and IL-13) in BALF than OVA-sensitization caused in 
old WT mice. This result is consistent with other observations showing that 
sensitization at an early age is associated with enhanced TH2 cytokine responses and 
adverse asthma outcomes45. H2S supplementation, at the time of initial allergen 
sensitization, limited type 2 response, promoted maturity of the immune system and 
abridged asthma development, whereas CSE gene knock-out enhanced type 2 
immune response and aggravated asthma symptoms. Inflammatory-cell infiltration in 
airways and TH2 cell cytokine levels in BALF were comparable between young and 
old CSE-KO asthmatic mice. These pathological changes were more severe than in 
asthmatic WT mice of the same ages. It is clear that the elimination of CSE 
expression abolished age-dependent asthma development and worsened allergic 
asthma at all ages. 
 
Using animals of different ages, we further confirmed the importance of CSE/ H2S in 
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modulating airway responsiveness. CSE expression in the airways increased in an 
age-dependent manner. Airway responsiveness to MCh challenge of young WT mice, 
in the absence of allergen exposure, was more than twice that of old WT mice. Higher 
airway responsiveness at a young age has been observed in many other studies46,95,193 
and is related to increased risk of asthma in childhood97,98. MCh challenge induced 
comparable airway responsiveness in young and old CSE-KO mice, an effect of 
similar magnitude to that in young WT mice. Therefore, low abundance of CSE in 
young mice or deficiency of CSE in CSE-KO mice may alter intrinsic properties of 
airway smooth muscle and lead to airway hyper-responsiveness because of decreased 
endogenous H2S production.  
 
Taken together, our findings in chapter 3 demonstrate the important role of CSE/H2S 
in regulating airway responsiveness and type-2 immunity. Results from chapter 4 not 
only confirm the findings in chapter 3 but also elucidate the different regulatory 
effects of the CSE/H2S pathway in TH2 and TH1 responses and an essential role of the 
CSE/H2S pathway in the inception of childhood asthma. These results speak to a H2S-
based therapeutic strategy for asthma.  
 
Does this age-dependent expression CSE in mice resemble that of humans? CSE 
proteins, but not CBS or MST proteins, were detected in human spleen samples. 
Peripheral blood mononuclear cells (PBMC) from human adults (38-55 years old) 
had more CSE proteins than umbilical cord-blood mononuclear cells (CBMC). 
Neither PBMC nor CBMC expressed CBS proteins. Low abundance of MST protein 
was detected in PBMC. Direct comparison of CSE expression levels in splenocytes 
from young and old humans would be ideal to confirm the relevance of our animal 
study. There are no commercialized infant or children spleen tissues. (It is somewhat 
difficult to obtain samples by collaborating with pediatric surgeons because non-
operative management of splenic trauma, with the potential of avoiding 
overwhelming post-splenectomy sepsis194,195, is especially beneficial to children.) 
Spleen and peripheral blood are two major immune-system components. Cells from 
peripheral blood (PBMC or CBMC in newborns) share many characteristics of 
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splenocytes in terms of composition and function. Both are widely used to study type 
2 immune response196.  Comparing adult PBMC and infant CBMC should be a good 
substitute for the direct comparison of splenocytes from young and old humans. 
Therefore, to study whether CSE expression in immune cells varies with age, we 
chose commercially-available PBMC and CBMC. 
 
It is currently unclear which specific cell type(s) express CSE in an age-dependent 
manner and which tuned the immune response in our study. We were restricted in 
exploring these questions due to lack of access to multi-channel flow cytometry. 
Based on our data and available literature169, we hypothesize that dendritic cells 
express CSE in an age-dependent manner. Sufficient endogenous H2S will modulate 
dendritic cells’ response to antigen stimulation and subsequently refine the activating 
signals sent to naïve T cells by dendritic cells. Dendritic cells express high levels of 
major histocompatibility complex class I/II molecules, and costimulatory molecules 
CD80/CD86 and CD40. They are the most proficient antigen-presenting cells in terms 
of processing inhaled allergens, peptide antigens and soluble protein antigens. After 
taking up the antigen, dendritic cells migrate to the draining lymph nodes, where they 
activate and polarize naive TH cells197 .  
 
To test this hypothesis, our future study will include: 1) using multichannel flow 
cytometry to determine whether dendritic cells are the major source of CSE in 
splenocytes; 2) isolating dendritic cells from WT mice at different ages to test 
whether CSE expression in dendritic cells is age-dependent; 3) co-culturing dendritic 
cells from CSE-KO mice with naïve T cells isolated from WT mice to test whether 
deficiency of endogenous H2S in dendritic cells boosts their ability to induce TH2 
polarization; 4) in vitro experiments to observe which signal pathways in dendritic 
cells are changed by CSE/H2S expression levels; 5) isolating dendritic cells from 
CBMC and PBMC to confirm whether the phenomenon observed in mice is parallel 
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